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Abstract
Type 1 diabetes is an autoimmune disease caused by T-cell-mediated de-
struction of the insulin-producing beta cells of the pancreas. The exact 
mechanisms leading to type 1 diabetes are still mostly unknown, but ge-
netic and environmental factors are involved. This doctoral study aimed at 
characterizing novel immune responses associated with the development of
type 1 diabetes.
We were interested in peripheral immunological responses in T helper 
cells. One environmental factor we focused on was vitamin D, since epide-
miological data have associated it with type 1 diabetes and it has a direct 
effect on T cells. The aims of this study were to investigate the role of vit-
amin D during the fetal period for type 1 diabetes by analyzing first-tri-
mester serum samples from mothers of healthy and diabetic children. A low 
concentration of serum 25-hydroxyvitamin D (25(OH)D) during the first 
trimester of pregnancy was not associated with type 1 diabetes in the off-
spring. Furthermore, we investigated the possible protective role of vitamin 
D in beta-cell autoimmunity in young children from Finland and Estonia,
4two countries differing in the incidence of type 1 diabetes, standards of 
living, and vitamin D fortification of foods at the time of the study. We did 
not find differences in the vitamin D status or active hormone levels (1,25-
dehyroxyvitamin D (1,25(OH)₂D)) of vitamin D between the study groups.
Estonian children had lower 25(OH)D concentrations than Finnish chil-
dren, but their 1,25(OH)₂D concentrations were at the same sufficient level. 
Our results suggest that vitamin D deficiency in the first trimester of preg-
nancy is not a risk factor for the offspring developing type 1 diabetes later 
in life. Our results from young children further suggest that a low peripheral 
vitamin D concentration is not associated with the development of beta-
cell-associated autoimmunity.
Additionally, we investigated the timing of up-regulation of T helper 
(Th)17 immunity and the role of Th17 plasticity in the development of type 
1 diabetes in prediabetic children. Stimulated peripheral blood mononu-
clear cells (PBMCs) from children with multiple beta-cell autoantibodies 
and impaired glucose tolerance revealed up-regulation of Th17 immunity 
and increased mRNA expression of interferon-γ (IFN-γ) and interleukin-9
(IL-9). These children also had higher IFN-γ mRNA expression in fluores-
cence-activated cell sorting (FACS)-purified Th17 cells. We observed that 
Th17 immunity and increased plasticity of Th17 cells is associated with 
advanced beta-cell autoimmunity and it correlated with clinical parameters. 
Finally, we examined peripheral cytokine, chemokine, and growth factor
profiles in healthy children from Russia, Estonia, and Finland, countries 
with different incidences of type 1 diabetes and standards of living. We
observed that Finnish children had a lower concentration of epidermal 
growth factor (EGF) and soluble CD40 ligand (sCD40L) in their blood. We
observed higher mRNA expression of interleukin-22 (IL-22) in circulating 
memory T helper cells of Estonian children. We also noted that Th17 and 
5Th1 immunity-related cytokines were up-regulated in the blood of Finnish 
children.
To conclude, vitamin D is not a direct protective factor in the development 
of beta-cell autoimmunity or type 1 diabetes. Th17 immunity and plasticity 
associate with type 1 diabetes disease progression from advanced beta-cell 
autoimmunity to clinical disease. These data may provide new tools for 
improved disease development monitoring and for selecting individuals at 
risk to be included in secondary intervention trials. The low EGF and 
sCD40L levels in the blood of Finnish children may modulate the epithe-
lium of the intestine and hence result in altered T-cell differentiation, lead-
ing to pathogenic Th17 immunity. In the future, we should further focus on 
determining the relationship between vitamin D, EGF, and Th17 immunity,
since EGF may regulate immune cell functions either directly or indirectly 
through the regulation of epithelial integrity, which in turn may affect the 
risk of developing type 1 diabetes.
Keywords: Type 1 diabetes, T cell, Vitamin D, Th17 immunity, Epidermal 
growth factor
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Tiivistelmä
Tyypin 1 diabetes on autoimmuunisairaus, jossa elimistön T-solut aiheut-
tavat haiman insuliinia tuottavien beetasolujen tuhoutumista. Taudin syn-
tymekanismit ovat edelleen suurelta osin tuntemattomia, mutta tiedetään, 
että sekä geneettiset että ympäristötekijät osallistuvat prosessiin. Tämän 
tutkimuksen tarkoituksena oli kuvata uusia sairauden kehittymiseen liitty-
viä immuunivasteita.
Tutkimuksessa keskityttiin perifeerisiin immuunivasteisiin T-auttajasoluja 
analysoimalla, sekä ympäristötekijöistä D-vitamiinin, jonka on ajateltu 
mahdollisesti suoajaavan taudilta. Yhtenä tavoitteena oli määrittää seeru-
minäytteistä D-vitamiinitasoja (seerumin 25-hydroksi-D-vitamiini; 
25OHD) raskauden ensimmäisen kolmanneksen ajalta, ja tutkia, onko ta-
soilla merkitystä siihen, sairastuuko lapsi myöhemmin tyypin 1 diabetek-
seen. Alhainen seerumin 25(OH)D pitoisuus raskauden ensimmäisen kol-
manneksen aikana ei liittynyt taudin kehittymiseen lapsilla. Halusimme 
7myös tutkia D-vitamiinin mahdollista suojaavaa vaikutusta beetasoluau-
toimmuniteetille alttiissa nuorissa suomalaisissa ja virolaisissa lapsissa. 
Näissä maissa tyypin 1 diabeteksen ilmaantuvuus, elintaso sekä elintarvik-
keiden D-vitaminointi olivat tutkimuksen aikaan erilaisia. Emme kuiten-
kaan nähneet eroja ryhmien välillä, joilla oli eri riski sairastua tyypin 1 dia-
betekseen, D-vitamiinitasoissa tai aktiivisen hormonin (seerumin 1,25-di-
hydroksi-D-vitamiini; 1,25(OH)₂D) tasoissa. Virolaisilla lapsilla oli sel-
västi matalammat D-vitamiinitasot, mutta heidän 1,25(OH)₂D-pitoisuudet 
olivat samalla riittävällä tasolla kuin suomalaisilla lapsilla. Tuloksemme 
osoittavat, että D-vitamiinin puutos raskauden ensimmäisen kolmanneksen 
aikana ei ole riskitekijä tyypin 1 diabeteksen kehittymiselle lapsilla eikä D-
vitamiinilla ole suojaavaa vaikutusta beetasoluautoimmuniteetin kehitty-
miselle nuorissa lapsissa. 
Lisäksi halusimme selvittää aiemmin tyypin 1 diabetekseen liitetyn T-aut-
tajasolupopulaation (Th17-solut) aktivoitumisen ajoitusta tautiprosessissa 
ja Th17-solujen plastisuuden merkitystä taudin kehittymisessä prediabeet-
tisissa lapsissa. Osoitimme lisääntyneen Th17-immuniteetin stimuloiduissa 
perifeerisen veren mononukleaarisissa soluissa (PBMC) lapsilla, joilla oli 
useita beetasoluautovasta-aineita sekä heikentynyt sokerinsieto sokerirasi-
tuskokeessa. Näissä soluissa näkyi myös lisääntynyt interferoni-γ (IFN-γ) 
ja interleukiini-9:n (IL-9) mRNA ekspressio. Lisäksi havaitsimme samojen 
lasten virtaussytometrisesti puhdistetuista Th17-soluista lisääntyneen IFN-
γ mRNA ekspression. Havaitsimme, että Th17-immuniteetti sekä -plasti-
suus liittyy pitkälle edenneeseen beetasoluautoimmuniteettiin.
Lopuksi halusimme tutkia veren sytokiini-, kemokiini- ja kasvutekijäpro-
fiileja terveillä lapsilla Venäjältä, Virosta ja Suomesta, maista, joissa sekä 
tyypin 1 diabeteksen ilmaantuvuus että elintaso ovat erilaisia. Havait-
8simme, että suomalaisilla lapsilla oli alhaisempi epidermaalisen kasvuteki-
jän (EGF) ja liukoisen CD40-ligandin (sCD40L) pitoisuus veressä. Lisäksi 
havaitsimme korkeamman interleukiini-22 (IL-22) mRNA ekspression vi-
rolaisten lasten veren T-auttajamuistisoluissa. Huomasimme myös, että 
Th17- ja Th1-immuniteettiin liittyvät sytokiinit olivat suomalaisten lasten 
veressä koholla.
Tulosten perusteella voidaan todeta, että raskauden ensimmäisen kolman-
neksen tai varhaislapsuuden D-vitamiinitasoilla ei ole suoraa yhteyttä bee-
tasoluautoimmuniteetin tai tyypin 1 diabeteksen kehittymiseen. Th17-im-
muniteetti ja -plastisuus liittyvät taudin kehittymiseen ja täten näitä voitai-
siin mahdollisesti käyttää työkaluina riskiyksilöiden valinnassa interven-
tiotutkimuksiin. Suomalaisilla lapsilla havaitut matalat EGF- ja sCD40L-
pitoisuudet saattavat aiheuttaa muutoksia suoliston limakalvolle ja näin ol-
len muuttaa T-auttajamuistisolujen profiilia patogeenisten Th17-solujen 
suuntaan. Tulevaisuudessa olisi kiinnostavaa selvittää edelleen D-vitamii-
nin, EGF:n ja Th17-immuniteetin välisiä suhteita, sillä EGF saattaa sää-
dellä Th17-immuniteettia ja siten tyypin 1 diabeteksen kehittymistä.
Avainsanat: Tyypin 1 diabetes, T-solu, D-vitamiini, Th17-immuniteetti,
Epidermaalinen kasvutekijä
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2 Abbreviations
1,25(OH)2D 1,25-dihydroxyvitamin D
25(OH)D 25-hydroxyvitamin D
Aab- Autoantibody-negative
Aab+ Autoantibody-positive
Ab Antibody
Ag Antigen
AHR Aryl hydrocarbon receptor
AITR Activation-inducible TNFR family receptor
APC Antigen presenting cell
APECED Autoimmune polyendocrinopathy–candidiasis–ectodermaldystrophy/dysplasia
AREG Amphiregulin
ATP Adenosine triphosphate
BB Bio-breeding
BB-DP Bio-breeding diabetes prone
BB-DR Bio-breeding diabetes resistant
BCG Bacillus Calmette–Guérin  
BCL-2 B-cell lymphoma 2
BCR B-cell receptor
BID BH3 interacting-domain death agonist
BMI Body mass index
BSA Bovine serum albumin
CCR Chemokine receptor
CD Cluster of differentiation
CIT Citron kinase
15
COX-2 Cyclooxygenase-2
C-peptide Connecting peptide
CSK Tyrosine-protein kinase
CTL Cytotoxic T-lymphocyte
CTLA Cytotoxic T-lymphocyte-associated antigen
CV Coefficient of variation
CYP Cytochrome
DC Dendritic cell
DEQAS Vitamin D external quality assessment scheme
DIPP Diabetes prediction and prevention
EAE Experimental autoimmune encephalomyelitis
EGF Epidermal growth factor
EIA Enzyme immunoassay
ELISA Enzyme linked immunosorbent assay
EMCV Encephalomyocarditis virus
FACS Fluorescence-activated cell sorting
FasL Fas ligand
FDA Food and Drug Administration
FITC Fluorescein isothiocyanate
FMC Finnish maternity cohort
FOXP3 Forkhead box P3
GADA Glutamate decarboxylate autoantibody
GC Group-specific component
GDM Gestational diabetes
GITR Glucocorticoid-induced TNFR-related
GM-CSF Granulocyte-macrophage colony-stimulating factor
H₂SO₄ Sulfuric acid 
HbA₁c Glycated hemoglobin A?c
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HLA Human leukocyte antigen
HRP Horseradish peroxidase
IA-2A Tyrosine phosphatase-like protein autoantibody
IAA Insulin autoantibody
IBD Inflammatory bowel disease
ICAM Intercellular adhesion molecule
IFN Interferon
Ig Immunoglobulin
IGF Insulin-like growth factor
IGT Impaired glucose tolerance
IL Interleukin
IL-17R IL-17 receptor
IL-22BP IL-22 binding protein
ILC Innate lymphoid cell
INS Insulin
IPEX Immunodysregulation polyendocrinopathyenteropathy X-linked syndrome
ITPR Inositol 1,4,5-trisphosphate receptor
iTreg Induced Treg
JAK-STAT Janus kinase-signal transducer and activation of transcription
KIR Killer-cell immunoglobulin-like receptor
LAG-3 Lymphocyte activation gene 3
Lti Lymphocyte tissue inducer 
Lyp Lymphoid-specific phosphatase
MARD Mild age-related diabetes 
MHC Major histocompatibility complex
MOD Mild obesity-related diabetes 
MODY Maturity-onset diabetes in the young
17
MS Multiple sclerosis
MyD88 Myeloid differentiation primary response gene
NFκB Nuclear factor κB
NK Natural killer
NMO Neuromyelitis optica 
NO Nitric oxide
NOD Non-obese diabetic
NOS2A Nitric oxide synthase 2A
nTreg Natural Treg
PAMP Pathogen-associated molecular pattern
PASW Predictive Analytics SoftWare 
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PD Programmed cell death
PE Phycoerythrin
PerCP Peridinin Chlorophyll Protein Complex
PLN Pancreatic-draining lymph nodes 
PRR Pattern recognition receptors 
PTPN Protein tyrosine phosphatase, non-receptor
RA Rheumatoid arthritis
RANTES Regulated on activation, normal T cell expressed and secreted
RIA Radioimmunoassay
RNASeq RNA sequencing
ROR RAR-related orphan receptor
RT-qPCR Reverse transcription quantitative polymerase chain reaction
RU Relative unit
Runx1 Runt-related transcription factor 1
SFB Segmented filamentous bacteria 
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SNP Single nucleotide polymorphism
SOD2 Superoxide dismutase 2
SPSS Statistical Package for the Social Sciences
STAT3 Signal transducer and activator of transcription 3
SUMO Small ubiquitin-related modifier
T1D Type 1 diabetes
T2D Type 2 diabetes
T-bet T-box transcription factor
TCR T cell receptor
TNF-α Tumor necrosis factor alpha
TGF Transforming growth factor
Th T helper
TH Tyrosine hydroxylase
TLR Toll-like receptor
TMB Tetramethylbenzidine
TNF Tumor necrosis factor
TR1 T regulatory type 1
Treg Regulatory T cell
tTreg Thymic regulatory T cell
UC Ulcerative colitis
VDR Vitamin D receptor
VNTR Variable number of tandem repeats
ZnT8 Zinc transporter 8
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3 Introduction
Type 1 diabetes is one of the most common chronic diseases, often devel-
oping during early childhood. Despite decades of research, there is no cure 
for type 1 diabetes or treatment to stop disease development, and accom-
panying chronic conditions such as renal, kidney, and eye failures are con-
sequently common in patients with type 1 diabetes. This underlines the im-
portance of research regarding the mechanisms of disease development.
Type 1 diabetes is an immune-mediated disease in which T cells destroy 
the insulin-producing beta cells in the pancreas. This leads to the loss of 
sufficient insulin production and, without insulin treatment, death of the
patient. The process during which the beta cells are destroyed can continue
for a varied amount of time. This period is characterized by the appearance
of disease-associated autoantibodies in the blood. The exact molecular 
mechanisms of this destruction and the factors that lead to it are mostly 
unknown. The strong genetic susceptibility to type 1 diabetes does not ex-
plain the gradual increase in disease incidence, and environmental factors 
modulating the disease risk therefore need to be studied. Factors thought to
be involved in disease development as either triggers or promoters include
nutrition, infections, alterations in the microbiota, and toxins. T cell subsets 
and responses involved in disease development have been investigated to 
find a way to stop the beta-cell destruction. 
This doctoral study aimed at characterizing T cell responses during the pre-
clinical phase of type 1 diabetes. The association between vitamin D and 
type 1 diabetes, the timing of Th17 immunity during disease development,
and the role of mucosal immunity were studied.
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4 Review of the literature
The immune system protects us from pathogens, foreign substances, and 
aberrancies occurring in our own cells. This complex system consists of
different organs, cells, and proteins. Along with the nervous system, the 
immune system is the most complex system that the human body has. The 
first of the main responsibilities of the body's immune system is to neutral-
ize pathogens such as bacteria, viruses, parasites, or fungi that have entered 
the body, and to eradicate them. The second task is to recognize and neu-
tralize harmful environmental substances and to tolerate harmless or bene-
ficial commensals, nutritional antigens, and other structures. The third as-
signment is to fight the body’s own harmful cells such as cancer cells. The 
following chapters of this literature review describe important cells and 
mechanisms of the immune system, with the emphasis on those important 
for this study, the pathogenesis of type 1 diabetes and finally the association 
of environmental factors and immunological aberrancies with type 1 dia-
betes development.
4.1 The innate immune system
The innate immune system is designated as the first line of defense of an 
organism against pathogens. Innate immunity consists of multiple different 
cells that originate from a common myeloid progenitor cell, such as mac-
rophages, granulocytes (neutrophils, eosinophils, basophils), and dendritic 
cells (DCs). These three cell types are called phagocytes, since they can 
engulf and kill pathogens and induce inflammation. This attracts other im-
mune cells to the site of infection. Another innate immune cell type is the 
21
natural killer (NK) cell, which is mainly able to recognize and kill abnormal 
cells such as those infected with viruses and tumor cells.
DCs, macrophages, and neutrophils recognize and distinguish foreign par-
ticles with pattern recognition receptors (PRRs) such as toll-like receptors 
(TLRs) and scavenger receptors at the site of infection. They recognize 
pathogen-associated molecular patterns (PAMPs) such as mannose-rich ol-
igosaccharides, peptidoglycans, lipopolysaccharides, and peptides that
many pathogens express. After signal recognition and engulfing of the for-
eign material, macrophages and DCs migrate into lymph nodes and become 
active antigen-presenting cells (APCs). In the lymph nodes, the antigen is 
processed and displayed on the cell surface of the APCs bound to major 
histocompatibility complex (MHC) molecules. These APCs become acti-
vated and produce cytokines and chemokines to recruit more immune cells 
to the site of infection, and present antigens to T lymphocytes for activation 
[1]. In humans, MHC molecules are called human leukocyte antigens
(HLA), since they were first discovered on leukocytes. MHC class I pro-
teins present antigens to CD8+ cytotoxic T cells, and MHC class II mole-
cules present antigens to CD4+ helper and regulatory T cells. This activates 
the adaptive immune system [2]. Co-stimulatory molecules such as CD80
and CD86 are expressed on the surface of DCs, and they are necessary for 
T cell activation through their interaction with the co-stimulatory CD28
molecule on the surface of the T cell [3, 4].
4.2 The adaptive immune system
The response of the adaptive immune system to pathogens is more specific
than the response of the innate immune system. The adaptive immune sys-
tem is highly developed and only present in vertebrates with jaws (gnatho-
stomes) [5]. It generates responses against a wide variety of antigens and 
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provides long-lasting immunity. The effector cells of the adaptive immune 
system are lymphocytes, which display a large variety of antigen receptors 
on their cell surface. These cells respond to antigens by proliferating and 
differentiating into clonal effector cells [6].
Lymphocytes can be divided into bone marrow-derived B cells responsible 
for humoral immune responses and thymus-derived T cells responsible for 
cell-mediated immune responses. Both cell types have their own type of 
antigen receptor, the B cell receptor (BCR) on B cells and the T cell recep-
tor (TCR) on T cells. T cells can be divided into cytotoxic T cells (CD8+ 
Tc 4.2.1) and helper cells (CD4+ Th 4.2.2). In order to establish a wide 
variety of antigen receptors, surface receptors are generated through so-
matic recombination and hypermutation [7]. BCRs bind to epitopes, which
leads to the activation and differentiation of B cells into antibody-secreting 
plasma cells. Th cells are needed for B cells to differentiate into plasma 
cells. These then secrete antibodies that bind to target antigens and initiate 
the neutralization or destruction of the target. In addition to antibody secre-
tion, B cells present antigens to CD4+ Th cells on MHC class II molecules
[8]. Recently, Hong et al. reported that B cells were the dominant cell pop-
ulation to present antigens to naïve CD4+ T helper cells upon immunization 
[9].
T cell development begins with lymphoid progenitors in the bone marrow. 
These then migrate into the thymus in order to fully mature [10]. Double-
positive cells (which express both CD4 and CD8 receptors) are further se-
lected and tested for their T cell receptors (TCRs) to interact with MHC 
molecules with at least a weak affinity to ensure reactivity [11]. After pos-
itive selection, developing naïve T cells are subjected to negative selection 
in the thymus. During negative selection, self-antigens are presented to the
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naïve T cells. Negative selection leads to the deletion of T cell clones car-
rying TCRs that recognize self-antigens with an excessively high affinity. 
Mature naïve T cells express either CD4 (Th cells) or CD8 (CTLs) co-re-
ceptors and leave the thymus to reside in lymphoid tissues, where antigens
are presented to them by activated DCs. Subsequently, activated naïve T 
cells differentiate into effector and memory T cells. Memory cells are fur-
ther divided into central memory cells (Tcm) and effector memory cells 
(Tem). Central memory cells lack immediate effector functions and they 
home to secondary lymph nodes, where they can be reactivated [12]. Ef-
fector memory cells display receptors for homing to inflamed tissues and 
express immediate effector functions [12]. Memory cells can survive for 
many years. Different mechanisms are involved in T cell activation, of 
which the first and second are obligatory: 1) HLA–antigen epitope–TCR 
interaction, 2) co-stimulation, 3) interaction of cell–cell adhesion mole-
cules, and 4) cytokine secretion by APCs. Conventional T cells cannot bind 
antigens directly, but the TCR binds antigen epitopes bound to the MHC
molecules on the surface of DCs, macrophages, and B cells.
With the help of the innate system, the adaptive immune system is respon-
sible for generating an immunological memory. This leads to rapid recall 
responses to antigens that have previously been encountered. Both T and B 
cells can become long-lived memory cells that generate a fast recall re-
sponse to secondary pathogen challenge [13].
Two important mechanisms preserve immunological homeostasis and the
self-tolerance of T cells: central and peripheral tolerance. T cells with an 
excessively high TCR affinity towards peptides from self-proteins pre-
sented on MHC molecules are deleted in the thymus of healthy individuals,
and this is referred to as central tolerance [14]. When these autoreactive T 
cells are not deleted but released from the thymus to the peripheral blood 
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stream, they can still be controlled through peripheral tolerance mecha-
nisms [15], the most important of which involves regulatory T cells 
(4.2.2.4). When these mechanisms fail, autoimmunity can occur.
4.2.1 Cytotoxic T cells
Cytotoxic T cells protect against intracellular pathogens residing in the cy-
tosol, such as viruses, some bacteria, and parasites. They kill infected cells 
before the microbes can proliferate and escape to infect more cells. DCs
activate cytotoxic T cells to become effector cells that recognize target cells 
displaying the same antigen as presented to them by the DC. They express
the co-receptor CD8, which recognizes the invariant region of the MHC I 
protein. Two main mechanisms are responsible for the killing of the target 
cell: 1) perforin–granzyme-dependent killing and 2) Fas-dependent killing
[16-18]. In the first, the T cell releases a pore-forming protein, perforin, to 
form transmembrane channels in the plasma membrane of the target cell.
Serine proteases enter the target cell through the channels and activate 
apoptosis through the protease granzyme B interacting with a pro-apoptotic 
protein called Bid, which through its truncated form releases cytochrome c 
from mitochondria, leading to the caspase cascade and apoptosis. The sec-
ond mechanism goes through Fas–Fas-ligand activation, where an adapter 
protein binds to the Fas–Fas-ligand complex and then binds procaspase 8, 
which in turn becomes activated and leads to the caspase cascade and apop-
tosis. A third method to enhance the destruction of the target pathogen is 
the release of cytokines [19]. CD8+ T cells secrete interferon (IFN)-γ and 
TNF-α, which are able to inhibit viral replication, activate macrophages, 
and enhance MHC class I expression and apoptosis of the target cell.
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4.2.2 T helper cells
Th cells are an important component of the adaptive immune system. They 
interact with cells of both the innate and adaptive immune system, respond-
ing to signals from DCs in particular. As mentioned previously, naïve 
CD4+ T helper cells differentiate into distinct subsets after ligation of the
TCR to the peptide bound to the MHC class II molecule. Co-stimulatory 
proteins binding to co-stimulatory receptors, cell–cell adhesion formation,
and cytokines also direct their differentiation. They display the co-receptor 
CD4, which binds to the invariant region of the MHC II molecule. A small 
part of these cells differentiate into long-lasting memory cells. The cyto-
kine environment, the antigen, and the strength of stimulation are factors 
that affect the different Th cell outcomes (Figure 1). It has previously been 
thought that different subsets target specific pathogens and secret specific 
cytokines, but recent results have shown that cells go through different fates 
during their lifespan rather than commit to a single fate [20].
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Figure 1. T helper cell differentiation and plasticity. The black arrows describe the cyto-
kines directing the differentiation of different T helper types. The purple lines suggest 
potential fates for an individual cell. Modified from [21] [22] and [23]. 
4.2.2.1 Th1 and Th2 cells 
The first T helper cells identified were Th1 and Th2 cells [24, 25]. Naïve T 
cells that are activated by interleukin (IL)-12, producing DCs, differentiate 
into IL-2 and IFN-γ producing Th1 cells [26]. These cells are activated dur-
ing infections with intracellular pathogens such as intracellular bacteria and 
viruses. Factors that favor Th1 differentiation include IFN-γ/signal trans-
ducer and activation of transcription-1 (STAT1), IL-2/STAT5, and IL-
12/STAT4 signaling, and strong TCR signaling [27]. More specifically, the 
Janus kinase-STAT (JAK-STAT) pathway plays an important role in signal 
transduction from the cell membrane to the nucleus of the cell (reviewed in 
[28]). JAKs are tyrosine kinases associated with membrane-bound cytokine 
receptors. Receptor activation results in trans-phosphorylation of JAKs, 
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leading to the recruitment, dimerization, and phosphorylation of STATs. 
These then migrate to the nucleus and regulate the transcription of their 
target genes. There are four human JAKs and seven human STATs. Th1 
cells need at least TYK2, JAK2, STAT1, and STAT4 for polarization [28].
Th2 cells need JAK1, JAK3, and STAT6 for differentiation. STAT5A/B 
and STAT3 have also been observed to be involved in Th2 polarization
[28]. Th1 cells activate macrophages to destroy infected cells, regulate Ig
class switching on B cells, and provide help to CD8+ T cells. Th1 cells are 
also involved in autoimmunity [27]. The signature cytokine of Th1 cells, 
IFN-γ, causes increased expression of TLRs, MHCI and MHCII antigen 
presentation, chemokine secretion, and increased activation and phagocy-
tosis of macrophages [27]. Th2 cells are differentiated under IL-4 signaling
and produce IL-4, IL-5, IL-9, IL-10, and IL-13 cytokines. These are im-
portant in the fight against multicellular pathogens such as helminths.
Overactivation of Th2 cells has been associated with allergies and atopic 
illnesses. The master transcription factors regulating each fate are T-bet for 
Th1 cells and GATA3 for Th2 cells.
4.2.2.2 Th17 cells
Th17 cells play an important role in the defense against extracellular bac-
teria, fungi, and other eukaryotic pathogens, but they are also associated 
with autoimmune diseases [29]. One of the functions of Th17 cells is to 
support innate immune responses against extracellular bacteria and fungi 
in the gut [30] and other mucosal surfaces. The presence of transforming 
growth factor (TGF)-β, IL-21, IL-6, or IL-1β induces the population of 
Th17 cells [31, 32]. In addition to IL-17, these cells also produce IL-21, IL-
22, IL-25, and IL-26. Th17 cells express the chemokine receptor CCR6,
which has only one known ligand, CCL20, and is specific to immune cells 
originating from the intestine and mesenteric lymph nodes [33] [34]. Th17
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cells are commonly found in the lamina propria of the small intestine under 
homeostatic conditions. The normal microbial flora in the intestine affects 
the development of Th17 cells. The transcription factor specific for Th17 
cells is retinoic acid receptor-related orphan receptor (ROR) γt [35]. Quite
recently, it was observed that RORα regulates the same genes as RORγ, but
in a slightly weaker way [36]. The involvement of all JAKs, along with 
STAT3, has been recognized to be important for Th17 polarization [37,
38].
4.2.2.3 Th9 and Th22 cells
Th9 and Th22 cells have been linked to both disease development and the 
preservation of immune homeostasis, and it remains to be seen what the 
most important functions of these cells are. Th9 cells are generated in the 
presence of IL-2, IL-4, TGF-β, and IL-1, while IFN-γ inhibits Th9 differ-
entiation [39, 40]. IL-4 and TGF-β induce expression of the PU.1 transcrip-
tion factor, leading to the differentiation of Th9 cells [27]. Duhen [41] and 
Trifari [42] identified the Th22 cell subset. These cells have been described 
as inflammatory, but they also have a tissue regenerating function. They 
secrete IL-22 and are differentiated through IL-6 and TNF by inducing the 
aryl hydrocarbon receptor (AHR) [27]. Both Th9 and Th22 cell subsets 
need further research on their role in regulating immune responses.
4.2.2.4 Regulatory T cells
Regulatory T cells (Tregs) express CD4, CD25, and the transcription factor
FOXP3, and they secrete TGF-β and IL-10. Tregs are usually divided into 
two groups depending on their origin: thymic-derived (tTregs) and periph-
erally inducible Tregs (iTregs). tTregs derive from positively selected thy-
mocytes with a relatively high TCR affinity for self-antigens presented on 
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the MHC II. One of the main functions of Tregs is to maintain self-toler-
ance. They were first described in mice and subsequently also in humans 
[43, 44]. Inducible Tregs can be generated from mature T helper cells under 
the influence of TGF-β and IL-2 [45, 46]. They are usually activated in
inflammation, autoimmunity, and cancer. In the mid-1990s, it was noted
that in mice, the removal of CD25+CD4+T cells produced a wide range of 
autoimmune diseases immunologically similar to human diseases such as 
autoimmune gastritis, thyroiditis, and type 1 diabetes [43]. A third type of 
regulatory T cells, T regulatory type 1 (Tr1) cells, secrete high levels of IL-
10 and express the cell-surface markers CD49b and LAG-3 but lack
FOXP3 expression [47].
The transcription factor FOXP3 is needed for the generation and function 
of Tregs, and patients with immunodysregulation polyendocrinopathy en-
teropathy X-linked (IPEX) syndrome suffer from autoimmune conditions 
such as type 1 diabetes, allergies, and autoimmune skin conditions due to a 
mutation in the FOXP3 gene [48-50]. STAT5 binds to the promoter region 
of FOXP3 and regulates its transcription [51]. Another marker especially
characterizing tTregs is the transcription factor Helios. It has been sug-
gested to be a marker for a thymic origin and for a more active and sup-
pressive phenotype of Tregs [52].
Various mechanisms have been suggested for Treg-mediated suppression.
These include cell contact-dependent and humoral factor-mediated mecha-
nisms with the involvement of a wide number of molecules, including cell 
surface molecules (CTLA-4, CD25 and TIGIT), cytokines (IL-2, IL-10,
and TGF-β), and secreted or intracellular molecules (granzyme and cyclic 
AMP) (reviewed in [53, 54]). Importantly, the expression of FOXP3 in 
non-Tregs provides them suppressive activity, indicating that FOXP3 is es-
sential in mediating suppression [55].
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Beyond functioning in the suppression of inflammation, Tregs are also pre-
sent in healthy tissue, such as in healthy skeletal muscle, visceral adipose 
tissue, and the hair follicle stem cell niche [55]. There they are involved in 
tissue repair and hair regrowth via the production of the growth factors am-
phiregulin (AREG) and the Notch ligand family member Jagged 1 [56, 57].
4.2.2.5 The plasticity of CD4+ T helper cells 
Plasticity of T cells refers to phenotypic switching in response to the local 
microenvironment of the cells. It has been suggested that effector memory 
cells are highly plastic, while central memory cells are more stable [58].
Uncontrolled plasticity has been linked to autoimmune diseases such as in-
flammatory bowel disease, type 1 diabetes, and multiple sclerosis (MS)
[59-62] (reviewed in [63]).
The plasticity of Th17 and Treg cells in the context of disease development 
is explained in more detail in chapters 4.5.3 and 4.5.4.
4.3 The maturation of the immune system
The immune system of a newborn was previously thought to be naïve, but 
even neonatal T cells proliferate in response to many antigens, including 
allergens, autoantigens, and parasite antigens [64]. Antigen-specific reac-
tivity has been observed in umbilical cord blood mononuclear cells col-
lected at birth. During fetal life, infections and vaccinations of the mother 
already affect the immune system of the unborn child. Moreover, Th2 im-
munity dominates, since Th1 immunity and IFN-γ are highly toxic to the 
placenta, and Th1 immunity is only upregulated after birth, unless a prim-
ing microbial environment is absent during infancy. It has been observed
that IFN-γ upregulation in Th cells usually occurs after the first year of life. 
The principal stimulation of postnatal immune maturation comes from the 
31
microbial environment, especially the commensal microbiota. The matura-
tion of the gut microbiota is an individual process lasting for an indefinite
amount of time [65]. Infections in the gastrointestinal tract also affect im-
mune system maturation [64]. Studies have shown that the adult-equivalent 
levels of CD45RO-positive memory T cells are achieved on average only 
at the age of 15 years [64].
4.4 Classification of human diabetes
Diabetes in humans has traditionally been divided into four main types:
type 1 diabetes, type 2 diabetes (T2D), gestational diabetes (GDM), and 
other type of diabetes. Approximately 5–10% of individuals with diabetes 
have type 1 diabetes, which has previously been referred to as insulin-de-
pendent diabetes or juvenile-onset diabetes. Type 1 diabetes can be divided 
into type A, which is immune-mediated, and type B, which is idiopathic 
and very rare. 
Type 2 diabetes, also referred to as non-insulin-dependent diabetes or 
adult-onset diabetes, accounts for 90–95% of diabetes patients. It is a dis-
ease characterized by insulin resistance or insulin deficiency. Patients are 
often obese and obesity itself is the most common cause of insulin re-
sistance [66]. Weight reduction and/or medication usually improves insulin 
responsiveness but never restores it to normal. There is a strong genetic 
predisposition in T2D, but it is very complex and not fully defined [66].
Other rare diabetes types are often caused by monogenic defects in beta-
cell function. Examples of these types are maturity-onset diabetes in the 
young (MODY), which is characterized by impaired insulin secretion but 
minimal or no defects in insulin action, and neonatal diabetes, which is di-
agnosed during the first six months of life and can be permanent or transi-
ent.
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4.5 Type 1 diabetes
Type 1 diabetes is an autoimmune disease where the insulin-producing beta
cells of the Langerhans islets in the pancreas are destroyed. This leads to 
the loss of blood glucose control and hyperglycemia. If the condition is not 
treated with exogenous insulin, it can result in ketoacidosis, blindness, re-
nal failure, and cardiovascular disease, and even death [67]. Even with bal-
anced treatment, type 1 diabetes may shorten life by as much as 10 years
on average [68]. The criteria for a type 1 diabetes diagnosis are: 1) classic 
symptoms with plasma glucose concentration ≥ 11.1 mmol/l or 2) fasting 
plasma glucose ≥ 7.0 mmol/l or 3) two-hour postload glucose ≥ 11.1 
mmol/l during an oral glucose tolerance test (OGTT) or 4) HbA1c ≥ 6.5% 
[69, 70]. Millions of people have been diagnosed with type 1 diabetes 
worldwide, and young children are especially affected. Approximately 
96 000 children under 15 years of age are estimated to develop type 1 dia-
betes annually [69]. Worldwide, the highest incidence is in Finland, where 
the incidence peak was observed in 2006 in children aged under 15 years,
with 64.9 per 100 000 person years [71]. Type 1 diabetes often begins at an 
early age, in childhood or adolescence, but it is even possible to be diag-
nosed with the disease as an elderly person [66]. In 2018, 70% of patients 
diagnosed in Finland were younger than 20 years old and 15% were over 
30 years old [72]. Diagnosed patients older than 50 years are rare, and in 
Helsinki, Finland, for example, only 1 to 3 are diagnosed per year [72].
Patients with type 1 diabetes are often prone to other autoimmune diseases. 
The most frequent diseases reported include Hashimoto's thyroiditis and 
Graves' disease, collectively referred to as autoimmune thyroid diseases 
(15–30% of type 1 diabetes patients), celiac disease (4–9%), autoimmune 
gastritis/pernicious anemia (5–10%), Addison's disease (0.5%), and vitiligo 
(2–10%) [73]. In Finland, hypothyreosis is the most common additional 
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autoimmune disease, with the disease being three times more common in 
patients with type 1 diabetes compared to controls (18.1% vs 6.0%) [74].
Mäkimattila et al. observed that hyperthyreosis was present in 2.4% of pa-
tients compared with 0.8% of controls, Addison’s disease in 0.38% of pa-
tients compared with 0.016% of controls, and celiac disease in 4.4% of pa-
tients compared with 0.99% of controls [74].
One recent study investigated the incidence rise in children under the age 
of 15 years in 22 countries, finding an overall increase of 3.4% (95% CI 
2.8% to 3.9%) in the incidence rate per annum [75]. The new developing
technology of insulin pumps and glucose meters has improved and simpli-
fied the efficient treatment of type 1 diabetes patients, but the burden still 
remains for the rest of the patient’s life, and life-long treatment requires
high motivation and competence from the patients and their families.
Therefore, it is desirable to either try to cure the disease with the help of 
transplantations or to stop or prevent the destructive process, or even re-
generate already lost beta-cell function [76]. One of the most challenging 
tasks is to arrest the disease process, since the mechanisms leading to it are
highly complex and multifactorial. Another factor that makes it difficult to 
find a solution is the fact that there seems to be high variance in metabolic 
profiles among patients. Therefore, individualized treatment and profiling 
should be a goal in the future.
4.5.1 Genetics of type 1 diabetes
It is well known that there is a genetic predisposition to developing type 1 
diabetes. Many genetic polymorphisms have been identified to be associ-
ated with type 1 diabetes, and certain HLA genotypes seem to be associated 
with the highest risk of developing the disease [77, 78].
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4.5.1.1 Genetic polymorphisms associated with type 1 diabetes
The most important risk genotypes are located in the HLA complex in chro-
mosome six and comprise half of the genetic component [79]. The HLA 
complex contains at least 128 genes and most of them are involved in im-
munity [80]. The HLA-DQA1 and HLA-DQB1 genes are the most im-
portant determinants of the disease risk, whereas HLA-DR genes have 
more of a modifying effect. The most common high-risk genotypes are the 
trans-heterodimers DRB1*03-DQA1*0501-DQB1*0201/DRB1*04-
DQA1*0301-DQB1*0302 (DR3-DQ2/DR4-DQ8) and the most protective 
genotype is DQA1*0101-DQB1*0602 (DR15(2)-DQ6) [79, 81, 82]. The 
analysis of DQB1 alleles often provides a good risk estimation when deter-
mining the alleles DQB1*02, DQB1*0302 or DQB1*0602 [83].
Numerous non-HLA genes associated with type 1 diabetes risk have been 
identified, many of them with small odds ratios, but at least four genetic 
polymorphisms have consistently been observed to be associated with the 
type 1 diabetes risk in independent studies [84]. These include the insulin 
(INS) gene, the cytotoxic T-lymphocyte-associated protein 4 (CTLA4), the
protein tyrosine phosphatasis pyrosine nonreceptor-type 22 (PTPN22) and
the IL-2R α-subunit of the IL-2 receptor complex locus (IL2RA) [84, 85].
The region around the INS gene on chromosome 11p15 was found to be 
associated with the risk of type 1 diabetes almost 30 years ago [86, 87]. The 
CTLA4 gene is located on chromosome 2q33. The role of CTLA4 is 
thought to be in regulating self-tolerance and hence preventing autoimmun-
ity [85]. CD4+ and CD8+ T cells express CTLA4, which binds B7-1 and 
B7-2 ligands involved in antigen presentation. The results regarding vari-
ants of the CTLA4 gene are somewhat controversial, but it has been shown 
that the most strongly associated single nucleotide polymorphism (SNP) is 
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A6230G in the 3`UTR [88]. PTPN22 encodes the protein lymphoid-spe-
cific phosphatase (Lyp), which is involved in suppressing T-cell activation
through TCR signaling by interacting with the C-terminal Src kinase (Csk)
[89]. The C1858T variant in the coding region of PTPN22 is associated 
with an increased risk of type 1 diabetes, but also of rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE), and Graves’ disease [85, 90].
The variant leads to a Lyp protein with enhanced binding properties to the 
Csk kinase, and hence a more efficient suppression of TCR signaling. This 
can lead to increased survival of autoreactive T cells or modified Treg func-
tions, leading to less effective suppression of autoimmunity [85]. ?
The identified genetic risk factors explain ~60% of the observed genetic 
predisposition and they have been recorded in several human populations. 
Other polymorphisms that have been studied but show an inconsistent as-
sociation with type 1 diabetes are the vitamin D receptor (VDR) polymor-
phisms, which have been associated with type 1 diabetes in Dutch, German, 
Bangladeshi Indian and Japanese populations, but not in British or Roma-
nian populations [85]. One rather recent study detected two VDR polymor-
phisms in Finnish pregnant mothers whose children later developed type 1 
diabetes: one in the VDR gene (rs4516035) and the other in the group-spe-
cific component (GC) gene (rs12512631) [91]. Many associations have 
been revealed in single studies so far, but it is likely that many more will 
be identified in the future.
4.5.2 Immunological aberrancies in type 1 diabetes
The pathogenetic mechanisms of type 1 diabetes have been studied in ani-
mal models such as the bio-breeding (BB) rat since the 1970s and non-
obese diabetic (NOD) mice since the 1980s [92, 93]. These animals spon-
taneously develop autoimmune diabetes and share similarities with the hu-
man disease. Both models present with polyuria, glycosuria, weight loss,
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and lymphocytic infiltration of the islets (insulitis) [92, 93]. Healthy NOD 
mice rapidly develop autoimmune diabetes after the transfer of T lympho-
cytes from diabetic mice [94]. Insulitis caused by Th1 cells secreting IFN-
γ leads to beta-cell damage and autoimmune diabetes [95]. Isolated islet-
specific CD4+ T cells secrete IFN-γ upon islet antigen stimulation com-
pared with control cells (not islet specific) that secrete IL-10 [96]. In hu-
mans, a threshold of >15 CD45+ cells/islet has been established for the 
definition of insulitis [97]. In human type 1 diabetes, islet cell autoantibod-
ies (ICA) against insulin (IAA), glutamic acid decarboxylase 65 (GADA),
islet antigen-2 (IA-2), and zinc transporter 8 (ZnT8) typically appear in the 
blood before the onset of clinical disease [98-101]. Islet antigen-reactive 
peripheral blood T cells have also been detected in type 1 diabetes [102].
The presence of autoantibodies probably reflects ongoing islet autoimmun-
ity, and they can be used for disease prediction. The appearance of autoan-
tibodies is considered the first stage of disease development. The presence 
of a persistent autoantibody, recognizing one antigen, is linked to a slightly 
increased risk of developing type 1 diabetes. The persistent presence of two
or more autoantibodies associates with a high risk of developing the dis-
ease, although the time to diagnosis can vary considerably [103]. It has 
been estimated that the risk of developing type 1 diabetes by the age of 15 
years is 0.4% when no autoantibodies are detected. When one autoantibody 
is present, the risk rises to 14.5%, and with multiple autoantibodies, the risk 
rises to 69.7% [104]. It has been observed that children with IAA or ZnT8 
as their first antibodies are younger than children with GADA or IA-2A as 
their first antibodies at the time of seroconversion [103]. Children with IA-
2A as their first antibody progress more rapidly to clinical disease than
children with the other antibodies as their first ones [103]. The second stage 
of type 1 diabetes development is characterized by dysglycemia along with 
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the presence of multiple autoantibodies, and the final stage is clinical dis-
ease with hyperglycemia. Since the time from seroconversion to clinical 
disease varies and cannot be fully predicted, it is of great importance to find 
new biomarkers associated with disease progression to help in disease pre-
diction and possible protection. 
The first studies on human islets in patients with type 1 diabetes were pub-
lished in the 1960s, in which the infiltration of immune cells in inflamed 
islets was described [105]. Later, it was observed that 40% of the islet-
infiltrating mononuclear cells were IFN-γ-secreting cells [106]. Willcox et 
al. demonstrated that the early phase of insulitis presented with a greater 
abundance of CD8+ T cells and macrophages and the later phase with
CD20+ B cells in large numbers. CD4+ T cells have been observed in all 
phases of insulitis [107]. It has been observed that there is variation be-
tween patients, especially in the number of infiltrating CD20+ B cells [108,
109]. Leete et al. also demonstrated that this difference in the B cell profile 
could be linked to the age of disease onset, since a CD20lo profile was 
detected in patients who were diagnosed at an older age (mean 13 years),
whereas a CD20hi profile was seen in younger patients (mean age at diag-
nosis 7 years) [109]. This has resulted in a hypothesis that there are at least 
two different forms of insulitis in humans and that the CD20hi profile is a 
more aggressive form [110]. Interestingly, it has been shown that beta cells
are still left in the pancreases of some type 1 diabetes patients who have 
lived with the disease for over 50 years [111]. The possible reasons for this
are speculated to be mitosis of beta cells in type 1 diabetes patients and the 
survival from autoimmune attack of some beta cells by unknown means
[112, 113]. It has been recognized that at least four different beta-cell types 
are present in the islets, and some of them might be more resistant to de-
struction [114]. The hyperexpression of HLA class I molecules on beta
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cells might be a factor separating these subtypes. It has also been observed 
that hyperexpression of the HLA class I decreases over time [115]. This 
might be one reason why there are individual forms of disease. Addition-
ally, it has recently been described that α and γ cells isolated from deceased 
human donors had the ability to differentiate into insulin-producing cells in 
response to glucose after reprogramming with the transcription factors pan-
creatic and duodenal homeobox 1 (PDX1) and MAFA [116]. When these
cells were transplanted into diabetic mice, the converted human α cells re-
versed diabetes and continued to produce insulin for a period of six months.
Studies in NOD mice have suggested that blocking IFN-γ function with 
either IFN-γ-specific antibodies [117, 118] or soluble IFN-γ receptors [119]
reduces the incidence of spontaneous diabetes and prevents diabetes by 
transferred splenocytes from diabetic NOD mice [120]. Furthermore, trans-
genic expression of IFN-γ in beta cells of diabetes-resistant mice induced
autoimmunity, resulting in overt diabetes [121]. In vitro studies have re-
vealed that IFN-γ is cytotoxic for beta cells. Exposure of human and murine 
islets to IFN-γ with either IL-1β or TNF-α induced beta-cell death in vitro,
while IFN-γ alone had no effect on beta-cell death (reviewed in [122]).
PBMCs from type 1 diabetes patients produced more IFN-γ upon stimula-
tion compared with healthy controls and patients with Grave’s disease 
[123]. Patients with an activating mutation in an IFN-γ activator (STAT3) 
display augmented IFN-γ production in T cells and they develop a broad-
spectrum autoimmunity that commonly includes type 1 diabetes [124].
The role of IL-17 in pathogenesis was first observed in murine models of 
type 1 diabetes. Elevated levels of IL-17 transcripts correlated with the pro-
gression of insulitis to disease in the pancreas and blood circulation of the 
NOD mouse [125, 126]. The study of Emamaullee et al. [127] revealed that 
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Th17 cells were involved in the effector phase of diabetes disease develop-
ment in the NOD mouse model. They administered IL-25/IL-17E to sup-
port Th2 immunity or anti-IL-17 to mice, and when given at the age of 10 
weeks, disease was prevented at the age of six months. Furthermore, it has 
been reported in the NOD mouse model that islet-targeted IL-2 stimulation 
of FOXP3+Tregs prevents diabetes [128].
In humans, a link between Th17 immunity and type 1 diabetes has been 
observed in multiple studies [21, 129-133]. Honkanen et al. [21] reported
that children with type 1 diabetes had increased IL-17 secretion and expres-
sion of IL-17, IL-22, and RORc2, but also FOXP3 transcripts upon T cell 
activation in vitro. Moreover, circulating CD4+ T memory cells in children
with type 1 diabetes had the same pattern of IL-17, IL-22, and FOXP3 
mRNA upregulation, also suggesting activation of the IL-17 pathway in 
vivo. IL-17 additionally had detrimental effects on human islet cells in 
vitro. It increased the transcription of SOD2 and, together with IL-1β and 
IFN-γ, the transcription of the inducible isoform of NOS2A and COX-2,
which are involved in the inflammatory response in islet cells. Furthermore,
it was observed that IL-17 inhibited the mRNA expression of the anti-apop-
totic gene BCL-2 and enhanced the pro-apoptotic effect of IL-1β+IFN-γ in 
mouse insulinoma cells and primary human islet cells. A study by Marwaha 
et al. [129] yielded similar results. They observed that children with type 1 
diabetes had elevated levels of CD45RA- CD25intFOXP3low cells that 
were not suppressive, and these cells secreted significantly more IL-17 than 
other FOXP3+ subsets. Furthermore, they showed that these type 1 diabe-
tes subjects had a higher proportion of both CD4+ and CD8+ T cells that 
secreted IL-17. It has been reported that isolated human FOXP3+ Tregs 
secrete IL-17 when they are stimulated with proinflammatory cytokines IL-
1β and IL-6, but retain their suppressive function [133]. In a study by Arif 
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et al. [130], circulating CD4+ T cells from type 1 diabetes patients showed 
a greater IL-17 response to stimulation with beta-cell-derived antigens 
compared to control T cells from control subjects. The authors also exam-
ined one case where up-regulation of IL-17A, IL-22, and RORC was ob-
served in islets close to diagnosis. Furthermore, they proved that IL-17 con-
tributed to the amount of apoptosis in human islets by increased nitrite re-
lease and up-regulation of IL-17RA in beta cells through STAT1 and 
NFκB. Ferraro et al. investigated the phenotype of Th17 cells and Tregs 
from pancreatic-draining lymph nodes (PLNs) and circulating blood of 
type 1 diabetes patients and healthy controls [131]. They found that type 1 
diabetes patients had an elevated frequency of Th17 cells in their PLNs but 
not in their blood compared to controls. Furthermore, Tregs isolated from 
PLNs of type 1 diabetes patients were observed to be dysfunctional. One 
further study demonstrated that IL-17A specifically contributes to the de-
velopment of type 1 diabetes by exacerbating beta-cell apoptosis and en-
hancing CCL20 secretion in the islets [132].
4.5.3 The plasticity of Th17 cells 
Accumulating evidence suggests that T-cell plasticity, phenotypic switch-
ing, and the polyfunctionality of T helper cell subsets is a phenomenon as-
sociated with tissue destruction in autoimmune and inflammatory diseases. 
Originally, these mechanisms probably evolved to enhance the capacity of 
our immune system to deal with changing challenges caused by diverse 
pathogens and environmental antigens. However, dysregulation of this sys-
tem can enhance the risk of autoimmunity. 
Th17 cells show substantial phenotypic plasticity. In addition to IL-17, they 
are also able to secrete other effector cytokines. Animal studies suggest that 
the plasticity of Th17 cells and the development of IL-17/IFN-γ or IL-
41
17/GM-CSF co-producers, in particular, is associated with the pathogenic-
ity of Th17 cells, for instance in multiple sclerosis (MS) [63]. Animal stud-
ies have demonstrated that Th17 cells from BDC2.5 mice (NOD mice ex-
pressing the BDC2.5 transgenic TCR) induce autoimmune diabetes in 
healthy recipients after their phenotypic shift to Th1 cells in vivo. The ex-
pression of IFN-γ was upregulated and that of IL-17 downregulated in these 
cells, and they infiltrated the islets and transferred diabetes [134, 135].
When the IFN-γ response was neutralized with antibodies, diabetes was 
inhibited, suggesting that the generation of a Th1 response from Th17 cells 
is important for disease development. The conversion of Th17 cells into 
double-positive Th1/Th17 cells has also been observed in humans with ju-
venile arthritis and Crohn’s disease [62, 136]. Moreover, it has been re-
ported that Th17 cells can convert into IL-4-secreting Th2/Th17 cells (rev. 
[63]).
It has been suggested that the IL-23 signaling pathway plays an important 
role in Th17 plasticity by decreasing FOXP3 expression and increasing 
IFN-γ secretion. In addition, the cytokine microenvironment is an im-
portant factor affecting this. Naïve T cells that are differentiated with IL-
1β, IL-6, and IL-23 differentiate into Th17 cells that are highly pathogenic,
causing neurological symptoms in experimental autoimmune encephalo-
myelitis (EAE), the most commonly used experimental model for MS
[137]. Psoriasis has been successfully treated with the blockade of the IL-
12/IL-23 p40 subunit, which leads to the decreased production of proin-
flammatory cytokines and the p19 subunit of IL-23 [138]. It has also been 
reported that Th17 cells specific to different antigens have distinct pheno-
types in humans. Staphylococcus aureus-specific Th17 cells produce IL-
10, whereas Candida albicans-specific Th17 cells produce IFN-γ [139]. A
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RORγt inverse agonist (TMP778) blocked human Th17 and Tc17 cell dif-
ferentiation and also modulated IL-17A production and inflammatory 
Th17-signature gene expression (IL17A, IL17F, IL22, IL26, CCR6, and 
IL23) in mature human Th17 effector/memory T cells [140]. Even though 
the number of double-positive IL-17+/IFN-γ+ cells was not altered upon 
administration of a ROR inverse agonist, the expression of both IL-17 and 
IFN-γ was inhibited at the mRNA level in NOD mice [141]. This also pre-
vented hyperglycemia and suppressed insulitis. 
In 2015, it was shown that Th17 cells can have a dual role in the autoim-
munity process in NOD mice. Bellemore et al. observed that CD4+ T cells 
from BDC2.5 mice could be differentiated into IL-22-producing, disease-
initiating Th17 cells driven by IL-23 and IL-6, or through stimulation with 
TGF-β + IL-6 into non-diabetogenic regulatory Th17 (Treg17) cells ex-
pressing high levels of AHR, producing IL-10 but reduced levels of IL-22 
[142].
IFN-γ+IL-17+ double-positive T cells have been observed in the colon 
lamina propria of IBD patients (reviewed in [60]). Th17 cells that line the 
gut mucosa do not normally induce inflammation, but have been shown to 
be necessary for the maintenance of normal barrier function of the gut. 
Commensal bacteria in the gut play a critical role in the differentiation of 
Th17 cells in the lamina propria. One recent study demonstrated that seg-
mented filamentous bacteria (SFB) induced Th17 cells with a dual TCR 
expression against both SFB epitopes and autoantigens from the lung, and 
this led to autoimmunity [143].
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4.5.4 The plasticity of Treg cells
The role of Treg plasticity in disease has been investigated, but the results 
remain inconsistent. In murine models of type 1 diabetes, converted Tregs 
have been recognized to be pathogenic [144].
FOXP3+IL-17+ double-positive T cells have been observed in the colon 
lamina propria of IBD patients (reviewed in [60]). Double-positive 
FOXP3+IL-17+ T cells were observed in higher frequencies in the blood 
of patients with UC and Crohn’s disease compared to healthy controls [59].
Putnam et al. investigated the number and suppressive ability of CD25high 
Tregs in type 1 diabetes patients and healthy controls and did not find any 
differences between them [145]. McClymont et al. also studied the plastic-
ity of Tregs in type 1 diabetes patients [61]. They found that the frequency 
of Tregs was similar in the peripheral blood of type 1 diabetes patients and 
healthy controls, but the number of double-positive FOXP3+IFN-γ+ Treg 
cells was higher in patients. A study investigating the role of Treg plasticity 
in MS, on the other hand, observed a higher frequency of IFN-γ-secreting 
FOXP3+ Tregs in MS patients compared with healthy controls [146].
These cells also displayed a reduced suppressive capacity when cultured in
vitro.
4.5.5 The destruction of beta cells in type 1 diabetes
The prediabetic period, during which beta-cell destruction occurs, can vary 
from a few months to more than a decade (reviewed in [147]). Currently,
there is no golden standard for direct assessment of the death of human beta
cells. The best method to indirectly assess beta-cell destruction or the func-
tional beta-cell mass is to measure C-peptide, the peptide that connects pro-
insulin’s A- and B-chain, which is co-secreted in a one-to-one molar ratio 
with insulin but is not first-pass cleared from the circulation by the liver 
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[148]. The C-peptide levels appear to be lower and hence beta-cell destruc-
tion is more severe in recent-onset patients younger than 7 years [110]. It 
is challenging to investigate the molecular mechanisms of beta-cell de-
struction in humans, since the pancreas is a retroperitoneal organ, only ac-
cessible for studying after the death of the patient, and identifying such 
cases in the prediabetic phase of the disease is difficult. It has been esti-
mated that only around 150 pancreases at disease onset or shortly after were
examined between the years 1902–2010 [149]. This has led to a few bi-
obanks collecting pancreatic samples from diabetic patients, but the num-
ber of recent-onset samples nevertheless remains small [110]. Therefore,
many results regarding molecular mechanisms come from animal models 
and other human samples such as blood cells. It is thought that apoptosis is 
the main pathway of human beta-cell death [107].
Different extracellular signals, ATP levels, phosphorylation cascades, and
the expression of pro- and anti-apoptotic genes regulate apoptosis. The pro-
cess that leads to beta-cell death, the caspase pathway, involves molecules 
such as the Fas ligand (FasL), perforin, TNF-α, IL-1, and nitric oxide (NO)
[150]. Interaction with other effector molecules such as IFN-γ and IL-17 
enhances the progression of apoptosis [21, 130]. Studies in animal models 
have revealed that the first cells infiltrating islets are macrophages and den-
dritic cells that present beta-cell antigens on their MHC class II molecules 
to naïve CD4+ T cells in PLNs [151]. This favors Th1 differentiation of the 
T cell, and these cells further enhance the destructive process by secreting 
IL-2 and IFN-γ, which leads to the secretion of IL-1β and TNF-α and re-
lease of free radicals, such as NO, from APCs and beta cells [151]. CD4+ 
T cells can also activate B cells to produce antibodies against beta-cell an-
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tigens. The cytokine milieu recruits CD8+ T cells to the islets and stimu-
lates the beta cells to secrete IL-15, further enhancing the attraction of im-
mune cells [152].
CD8+ T cells can directly cause beta-cell death by secreting perforin and 
granzyme to the extracellular space, which causes membrane disruption in
the target cell. This occurs when the beta cell presents self-antigens on 
MHC class I molecules that are recognized by the TCR of the CD8+ T cells 
[151]. The Fas/Fas L interaction between the beta cell and the CD8+ T cell 
also contributes to the apoptosis process by activating caspase-8 and 
caspase-3, leading to cell death.
IL-17 alone or in combination with IL-1β/IFN-γ up-regulates SOD2, COX-
2, and NOS2A expression in human islets. IL-17 causes inflammation and 
increases apoptosis. IL-17 alone also downregulates BCL-2 expression in 
the islet cells [21].
Cytokine combinations such as IL-1β/IFN-γ and TNF-α/IFN-γ cause 
STAT1 and NF-kB apoptosis pathway activation and up-regulation of IL-
17 receptor (IL17R) expression in human islets, rat beta cells, and INS-1E 
cells [130]. IL-17 signaling can thus promote inflammation in the cells and 
enhance the apoptosis process.
4.6 Environmental risk factors for type 1 diabetes
The reason why environmental factors have been implicated in disease de-
velopment in type 1 diabetes is the fact that disease concordance for 
monozygotic twins is only about 50%, and that incidence varies greatly in 
environmentally different populations with a similar HLA genotype back-
ground [153, 154]. What furthermore emphasizes the importance of envi-
ronmental factors is the fact that the incidence of type 1 diabetes is rising 
in individuals with moderate or low-risk HLA genotypes [69]. It has also 
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been observed in immigrant populations that the environment predisposes 
to the risk of developing type 1 diabetes [155-157]. The rate of the growth 
in type 1 diabetes incidence observed is also too rapid to be accounted for 
by genetic factors. Moreover, it has to be noted that the incidence drasti-
cally differs between regions with genetically similar populations but dif-
ferent childhood environments, such as Espoo in Finland, Tarto in Estonia,
and Petrozavodsk in Russia, where the respective incidence rates have been
estimated to be 57.6/100 000, 17.1/100 000, and 12.1/100 000 in children 
under the age of 15 years [158]. It is thought that environmental triggers 
act during the fetal period and/or childhood either alone or by interacting 
with genetic factors. This interaction determines whether a genetically-sus-
ceptible individual eventually develops the disease.
4.6.1 Infections
Due to the higher incidence rate of type 1 diabetes during fall and winter,
infections have already been suggested to be a risk factor for type 1 diabetes
since the 1920s. Moreover, quite recently, it was reported again that most 
diagnoses are made during the period from November to February [159].
A few years ago, it was reported that during winter, a more pro-inflamma-
tory transcriptomic profile of genes is prevalent [160]. The viral infections 
most strongly associated with the risk of type 1 diabetes development are 
infections caused by single-stranded RNA enteroviruses of the Picornaviri-
dae family [67]. There are more than 60 serotypes of enteroviruses, and the 
most widely known are the polioviruses [161]. Enterovirus infections are 
common among children and adolescents, and often remain subclinical or 
cause only mild respiratory symptoms. The first studies considering enter-
ovirus infections as a risk factor for type 1 diabetes were conducted as much
as thirty years ago [162]. Antibodies against coxsackievirus B serotypes 
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were detected in newly diagnosed patients with type 1 diabetes compared 
with controls [163]. One meta-analysis showed that enteroviral infections 
were associated with type 1 diabetes-associated autoimmunity and clinical 
type 1 diabetes at odds ratios of 3.7 and 9.8 [164]. Increased T cell re-
sponses to enteroviral antigens have been reported in patients with signs of 
beta-cell autoimmunity and patients with type 1 diabetes [161]. Children 
positive for multiple beta-cell autoantibodies have been observed to have
more enterovirus infections than control children, suggesting the involve-
ment of these infections in the preclinical phase of type 1 diabetes [165].
Children with type 1 diabetes-associated autoimmunity had more and ear-
lier infections than control children [166]. Coxsackie enterovirus infection 
has been more commonly detected in beta cells of type 1 diabetes patients 
compared to controls [167]. Enteroviral RNA is also more often found in 
diabetic patients, suggesting a longer persistence of the infections in pa-
tients compared to healthy controls or celiac disease patients [168]. On the 
other hand, there have also been studies with conflicting results from Italy 
and Germany [67]. Enteroviral infections in utero have also been suggested 
to increase the risk of type 1 diabetes development, although a recent study 
concluded that it is not a major risk factor for disease development [169-
171]. Respiratory infections have been linked to autoantibody seroconver-
sion in a German study and encephalomyocarditis virus (EMCV)-induced
autoimmune diabetes in specific mouse strains and milder disease in other 
animal models [67]. The exact mechanism by which viruses could induce 
type 1 diabetes is still unknown and needs further investigation.
4.6.2 Duration of breastfeeding
The effect of breastfeeding on type 1 diabetes development has been stud-
ied and it has been suggested that a longer period of breastfeeding may be
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protective [172, 173]. A short exclusive breastfeeding time has been asso-
ciated with autoantibody development in children with the HLA-DQ*0302 
risk allele [172]. A recent study also found that children with type 1 diabe-
tes were breastfed for a shorter period and introduced to cow’s milk earlier 
than their siblings [174]. Since many studies have been based on question-
naires, there is a risk of false results, and more research regarding the pro-
tective effect of breastfeeding is needed.
4.6.3 Nutrition
The role of nutrition at an early age has been investigated regarding type 1 
diabetes development. Cow’s milk proteins and cereals have been exam-
ined as risk factors. Studies from NOD mice have revealed that highly hy-
drolyzed casein formula lowered the incidence of diabetes [175, 176]. The 
use of highly hydrolyzed casein formula reduced the incidence of type 1 
diabetes-associated antibodies in young children with a genetic predisposi-
tion by more than 50% [175-177]. Moreover, the removal of bovine insulin 
from cow’s milk formula also significantly lowered the incidence of beta-
cell autoimmunity in young children with a genetic predisposition com-
pared to children who received a whey-based formula [178]. However, 
these results could not be replicated in a large cohort study, in which no 
difference in the risk of developing type 1 diabetes was detected in children 
who received a hydrolyzed formula compared with a conventional formula 
[179].
Since celiac disease is more common in type 1 diabetes patients than in
healthy subjects, and around 10% of patients suffer from it, the role of glu-
ten has been investigated and controversial results have been found [67].
Results from NOD mice indicate a clear prevention of autoimmune diabe-
tes with a gluten-free diet [180]. In addition, when a soy-based diet was 
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compared with a wheat-based diet, it was seen that a Th1-type response
was induced by the wheat-based diet [181]. A gluten- and cereal-free diet 
influences the gut microbiota and hence contributes to immune system mat-
uration. In an interesting case report, a six-year-old boy diagnosed with
type 1 diabetes had lived for three years without daily insulin shots by 
changing to a gluten-free diet [182]. Recently, it was found that later intro-
duction of gluten to the diet compared with earlier introduction was asso-
ciated with a higher risk of autoimmunity (<4 months compared with 4–9
months and >9 months) [183].
4.6.4 Vitamin D
Vitamin D and type 1 diabetes have been linked, because there is geograph-
ical variation in the prevalence of type 1 diabetes and vitamin D synthesis 
in the skin, with a gradient from the north to the south. In 2003, vitamin D 
fortification of milk and spreads was started in Finland, and this has been 
suggested as a potential explanation for the plateauing of the incidence rate 
of type 1 diabetes [71]. In vitro, vitamin D has been shown to protect rat 
pancreatic islets from IL-1β-induced destruction [184]. Vitamin D has been 
linked to enhanced FOXP3 expression in Tregs and cholecalciferol supple-
mentation has been shown to improve the Treg suppressive capacity in pa-
tients with recent-onset type 1 diabetes [185, 186]. This suggests that vita-
min D could be a beneficial immunomodulatory agent in combination ther-
apy strategies for type 1 diabetes. The vitamin D status affects insulin se-
cretion, as vitamin D increases intracellular calcium, which in turn de-
creases insulin secretion [187]. Infections that can be associated with the
autoimmune process of beta-cell destruction can be controlled by vitamin 
D, and it may directly reduce the autoimmune process of beta-cell destruc-
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tion [188]. Maternal vitamin D deficiency and its effect on fetal develop-
ment have been investigated in different studies. It has been observed that 
serum 25-hydroxyvitamin D (25(OH)D) concentrations are similar in the 
mother and the newborn [189]. Pregnancy is characterized by a Th2-dom-
inant T helper profile, and this shifts towards Th1 after delivery [190]. This,
together with a drop in serum 25(OH)D after birth, could affect the auto-
immune process in newborns genetically at risk of developing type 1 dia-
betes [191]. It seems that an increased maternal vitamin D intake via food 
or cod liver oil products has a risk-lowering effect on type 1 diabetes de-
velopment in the offspring, whereas vitamin D intake through supplements 
or multivitamins has no effect on type 1 diabetes development. This, on the 
other hand, means that the effect can also be due to other components and 
not vitamin D alone. The intake of vitamin D in early life has been associ-
ated with a lower risk of developing type 1 diabetes in a Finnish study 
[192]. On the other hand, it must be noted that children in Russian Karelia 
have a similar genetic susceptibility and circulating vitamin D concentra-
tions as Finnish children and still have a six times lower risk of developing 
type 1 diabetes [153, 193].
4.6.5 The “hygiene hypothesis” or “biodiversity hypothesis” and gut 
microbiota in autoimmune disease
The “hygiene hypothesis” postulates that autoimmune diseases are more 
common in countries with higher hygiene standards. This fits with the 
higher incidence of type 1 diabetes in countries having stricter hygiene
[194]. People in these countries are less exposed to infectious agents, sym-
biotic microorganisms, environmental microbes, and parasites, and this 
leads to an altered T cell balance, which might result in the development of 
autoimmune diseases [67]. The more recent “biodiversity hypothesis”
51
states in more detail that our contact with natural environments enriches 
our microbiome, enhances the immunological balance, and protects us 
from allergy and inflammatory diseases [195]. Two layers of biodiversity
protect us, the microbiota of the outer layer (soil, natural waters, plants, 
animals) and the inner layer (gut, skin, airways). Changes in the diet and 
antibiotic use have also contributed to the loss of biodiversity. Evidence 
from animal models supports the hypothesis. For example, NOD mice from 
cleaner colonies have a higher incidence of autoimmune diabetes [196].
The myeloid differentiation primary response gene (MyD88) knockout 
NOD mouse is a further example of how the microbiota affects diabetes 
development. MyD88 is an innate immunity-signaling molecule involved 
in toll-like receptor (TLR) signaling. Deletion of the MyD88 gene leads to 
alteration of the gut microbiota composition and the prevention of autoim-
mune diabetes in these mice under normal housing conditions [197]. In-
fants born naturally gain their gut microbiota from the mother, whereas in-
fants born through cesarean section gain their gut microbiota from the hos-
pital environment. Birth by cesarean section has been associated with the 
risk in developing type 1 diabetes [198]. Korpela et al. recognized that 
prematurely (PT) born infants (<35 weeks of gestation) had a less diverse 
gut microbiota than full-term (FT) born infants [199]. Fouhy et al. observed
that the impact of gestational age at birth persisted for many years. They 
found that PT children had a similar gut microbiota diversity at 4 years to
FT children at 2 years [65]. One of the first studies to show the importance 
of the gut microbiome in human type 1 diabetes patients revealed that chil-
dren with signs of beta-cell autoimmunity developed a less diverse and less
stable microbiome than their controls at toddler age [200]. A study by de 
Goffau et al. demonstrated a low abundance of lactate-producing and bu-
tyrate-producing gut bacterial species in children with signs of beta-cell 
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autoimmunity [201]. They also found an increased abundance of the Bac-
teroides genus in these children, consistent with previous results. 
Other findings from human studies suggest that gut microbiota composition 
affects the development of type 1 diabetes. Data from genetically predis-
posed infants during the time between positivity for autoantibodies and 
clinical type 1 diabetes suggests that there is a drop in diversity during this
time and a peak in the presence of inflammatory organisms, gene expres-
sion, and metabolites [202]. Probiotics are recommended for infants in 
some maternity and child health clinics in Finland from the age of two 
weeks along with the recommended vitamin D supplement. This recom-
mendation may vary between communes and is not a general guideline. In 
a recent study that included samples from Finland, it was shown that early 
exposure (0–27 days after birth) to probiotics reduced the risk of autoim-
munity in children with high-risk genotypes for type 1 diabetes compared 
to later probiotic supplementation, or to no supplementation [203].
The decrease in helminth infections in developed countries has also been 
speculated to be linked with the growing incidence of type 1 diabetes [67].
Different helminth parasites inhibited or slowed down autoimmune diabe-
tes development in NOD mice [204-206]. No human studies regarding hel-
minthes as vaccines in type 1 diabetes prevention have been reported yet,
but promising results have been seen in pilot clinical trials involving pa-
tients with IBD and MS [207, 208]. The side-effect of helminths is that they 
cause chronic IgE-mediated basophil and mast cell activation, which can 
be avoided by using antibodies that bind to the IgE receptor on basophils 
and mast cells [209].
4.6.6 Gut inflammation, immunity and type 1 diabetes
The role of gut leakiness, or increased intestinal permeability, has been 
studied in the context of type 1 diabetes since the late 1990s. Increased 
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permeability was observed in the stomach, small intestine, and colon of BB 
rats [210]. Later, it was shown that high-risk diabetes-prone rats (BB-DP)
had increased intestinal permeability compared to low-risk diabetes-re-
sistant rats (BB-DR) during the prediabetic phase [211]. Alterations in the
tight junction protein claudin were also seen. In humans, the protein zonu-
lin, which regulates intestinal permeability by modulating intracellular 
tight junctions of the gut epithelium, appears to be upregulated in patients 
with type 1 diabetes [212]. It has been suggested that the leakiness of the 
gut influences the immune response against self- and non-self antigens, and 
this might contribute to disease development. Lee et al. investigated gut 
barrier disruption and the rate of insulitis in NOD mice upon challenge with
different strains of the bacterium Citrobacter rodentium [213]. They 
demonstrated that mice infected with the wild-type strain developed insu-
litis faster than mice infected with a mutant strain that did not disrupt the 
gut barrier. They also found that infected mice had increased numbers of 
pancreatic-draining lymph node T cells compared with non-infected mice.
Interestingly, it has been observed that IL-22 is important in protective im-
munity against Citrobacter rodentium. Zheng et al. noticed that IL-22 
knockout mice died from Citrobacter rodentium infection and histological 
samples revealed increased mucosal hyperplasia and submucosal inflam-
mation compared to wild-type mice [214]. One study presented results 
from in vitro experiments in which the stimulation of keratinocytes with 
the supernatant of Th22 cells, or recombinant IL-22 and TNF-α, success-
fully inhibited Candida albicans infections and preserved epithelial health 
[215]. IL-22 is important in host defense and the preservation of mucosal 
integrity, but also in the inhibition of cytokine-induced beta-cell damage 
and induction of beta-cell regeneration in the NOD mouse [216-218]. The 
absence of IL-22 has led to systemic inflammation and delocalization of 
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the commensal bacterium Alcaligenes in IL-22 deficient mice. Alcaligenes
xylosoxidans-specific IgG concentrations have been seen in patients with 
Crohn’s disease [219].
Another factor related to the preservation and repair of the intestinal mu-
cosa is epidermal growth factor (EGF) [220]. In the gastrointestinal tract,
EGF participates in the maturation and maintenance of the intestinal epi-
thelium [221, 222]. During intestinal development, EGF has a significant 
role in establishing a selective intestinal barrier function (reviewed in 
[223]). Seven ligands have been reported to bind to and activate the EGF
receptor (EGFR) (reviewed in [224]). These ligands belong to a family of 
type II cytokines (so-called EGF-like family) that includes EGF, transform-
ing growth factor-alpha (TGF-α), heparin-binding EGF-like growth factor 
(HBEGF), betacellulin (BTC), AREG, epiregulin (EREG), and epigen 
(EPGN). Many studies in mice have suggested a link between EGF and 
diabetes [213, 225-227]. These have reported that EGF deficiency is asso-
ciated with diabetes, and that EGF induces beta-cell replication and insulin 
release, and together with ciliary neurotrophic factor (CNTF) restores in-
sulin production in damaged mouse beta cells. Recently, it was observed
that in newly diagnosed T2D patients, the concentration of the soluble re-
ceptor of EGF (sEGFR) was elevated and correlated positively with blood 
glucose levels but negatively with C-peptide and insulin levels [228].
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5 Aims of the study
“A current goal is to identify modifiable environmental factors or therapeu-
tics that mimic the effects of protective factors or alleles.” – John Todd
[229]
The aims of this study were to:
I. Investigate the role of vitamin D during the fetal period for type 1 diabe-
tes. We compared serum 25(OH)D levels during early pregnancy in moth-
ers of children who developed type 1 diabetes with those in control mothers 
of non-diabetic healthy children of the same age.
II. Investigate whether plasma 25(OH)D concentrations associate with the 
development of beta-cell-associated autoantibodies and the transcriptional 
activity of FOXP3 or the vitamin D3 convertase gene (CYP27B1) in CD4+ 
memory T cells.
III. Study temporal associations between the disease pathogenesis of type 
1 diabetes and upregulation of Th17 immunity and T cell plasticity.
IV. Investigate markers of mucosal immunity in young children from Rus-
sia, Finland, and Estonia.
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6 Subjects and Methods
6.1 Subjects
6.1.1 Subjects in study I
Serum samples have been collected from all pregnant women in Finland 
since 1983 (the Finnish Maternity Cohort, FMC). The FMC stores first-
trimester serum samples required for screening of infectious diseases from 
nearly all (98%) mothers during every pregnancy. Samples are stored at -
20 °C for future use.
For this study, 498 case mothers were selected using the Finnish Pediatric 
Diabetes Register. For each case mother, a control mother was selected ac-
cording to the withdrawal date of the serum sample. This resulted in 343 
case–control pairs. Samples from pregnancies of healthy siblings were col-
lected from 137 case mothers.
The mean storage time of the serum samples before vitamin D analysis was 
14.7 years (range 10–17 years). Samples were collected between the years 
1993–2000. The mean age at type 1 diabetes diagnosis was 3.4 years (range 
0–7 years). Written informed consent was obtained from all mothers and 
the ethics committee of the Hospital District of Helsinki and Uusimaa ap-
proved the study.
6.1.2 Subjects in study II
Children participating in the Finnish and Estonian segment of the DIA-
BIMMUNE study and the Finnish Type 1 Diabetes and Prediction (DIPP) 
study were screened for HLA-conferred susceptibility to type 1 diabetes
and for seropositivity to beta-cell autoantibodies. Fifty-four (47%) children 
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carried risk-associated HLA-DR/DQ genotypes (nine with a strongly in-
creased, 34 with a moderately increased, and nine with a slightly increased 
risk). Blood samples were collected between October 2010 and August 
2011. Cell separations were performed the day after blood collection. Sub-
ject characteristics are presented in Table 1. The local ethics committees
approved the study and written informed consent was obtained from the
parents of all participants.
Table 1. Subjects in study II
Study
Number of 
participants
Average 
age ± SD
in years
Female/Male
Autoantibody-
positive
DIABIMMUNE 
(Finnish 
segment)
43 3.9 ± 0.6 31/12 12
DIABIMMUNE 
(Estonian 
segment)
32 4.4 ± 0.4 24/8 6
DIPP 40 8.0 ± 3.0 18/22 18
6.1.3 Subjects in study III
This study included samples from 159 children. Of these, 28 were Finnish 
children with type 1 diabetes from Helsinki Children’s Hospital, 90 chil-
dren (57 Finnish and 33 Estonian) participated in the DIABIMMUNE 
study, and 41 participated in the DIPP study. The characteristics of the dif-
ferent study groups are presented in Tables 2 and 3. The categories based 
on OGTT testing were: 1) 2-hour post-load plasma glucose <7.8 mmol/l = 
normal glucose tolerance, 2) 2-hour post-load plasma glucose 7.8 to <11.1 
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mmol/l = IGT, and 3) 2-hour post-load plasma glucose ≥ 11.1 mmol/l = 
provisional diagnosis of type 1 diabetes, which has to be confirmed with 
repeated testing [69].
Table 2. Subjects for the study on the up-regulation of Th17 immunity
Number
Average 
age ± SD
in years
Female/
Male
Type 1 diabetes [T1D] 15 8.3 ± 5.5 6/9
Early beta-cell autoimmunity [AAb+] 29 5.7  ± 3.1 16/13
Advanced beta-cell autoimmunity and impaired glucose 
tolerance [IGT]
9 7.7  ± 4.3 2/7
Negative for beta-cell autoimmunity [Aab-] 80 4.8 ± 2.3 50/30
Table 3. Subjects for the study on the plasticity of Th17 cells
Number
Average
age ± SD
in years
Female/
Male
Type 1 diabetes [T1D] 13 10.2 ± 5.1 6/7
Early beta-cell autoimmunity [Aab+] 5 5.8  ± 3.5 1/4
Advanced beta-cell autoimmunity and impaired glu-
cose tolerance [IGT]
6 9.2  ± 4.5 0/6
Negative for beta-cell autoimmunity [Aab-] 8 5.5  ± 2.3 5/3
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Blood samples were analyzed the day after collection. The parents of the 
study subjects provided their written informed consent before sample col-
lection. The local ethics committees approved the study.
6.1.4 Subjects in study IV
In this study, we collected serum samples from 3-, 6-, 12-, 18-, 24-, and 36-
month-old children from Russia (60 children, n = 144), Estonia (46 chil-
dren, n = 128), and Finland (45 children, n = 126) from the birth cohort of 
the DIABIMMUNE study. Heparinized peripheral blood samples were col-
lected from the DIABIMMUNE young children’s cohort from 48 Finnish 
and 37 Estonian children. Children in the birth cohort had HLA-conferred 
susceptibility to type 1 diabetes, whereas children studied in the young chil-
dren’s cohort represented the general population in Finland and Estonia. 
All studied children were negative for type 1 diabetes-associated autoanti-
bodies. The parents of the study subjects provided their written informed 
consent before sample collection. The local ethics committees approved the 
study. 
6.2 Methods
Table 4. Laboratory methods used in this doctoral study.
Cell isolations and cultures Method Publi-cation
PBMC separation from peripheral blood Ficoll isogradient centrif-ugation
II, III, 
IV
Enrichment of CD4+ T memory cells Magnetic depletion II, IV
Purification of Th17 cells Secretion assay and sort-ing with FACSAria II III
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αCD3+αCD28 stimulation of PBMCs for 40 or 
72h Cell culturing III
Flow cytometry and cytokine analyses   
CD3, CD4, CD45RO, CD45RA Extracellular staining II, III,IV
IL-17, IFN-γ Secretion assay and sort-ing with FACSAria II III
High-sensitivity T cell assay Luminex IV
38-plex Immunology Multiplex assay Luminex IV
Th17 multiplex Luminex IV
EGF, TGF-α, sCD40L Luminex IV
Serum and plasma 25-hydroxyvitamin D and 
1,25-dihydroksyvitamin D measurements   
Serum levels of 25(OH)D EIA I
Plasma levels of 25(OH)D EIA II
Plasma levels of 1,25(OH)2D Delipidation and EIA II
Plasma amphiregulin measurements     
Plasma amphiregulin EIA IV
RNA isolation     
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Total RNA isolation from PBMCs, CD4+ T 
memory cells and Th17 cells Filtration technique
II, III, 
IV
Gene expression analyses     
FOXP3, CYP27B1, 18s1 RT-PCR and TaqMan II
IL-17A, IL-17F, IL-22, IL-9, IFN-γ, RORc, 
AHR, FOXP3, 18s RT-PCR and TaqMan III
IL-22, IL-17A, IFN-γ, FOXP3, 18s RT-PCR and TaqMan IV
6.2.1 Cell isolations and stimulations
Plasma samples were collected before Ficoll (GE Healthcare, Uppsala, 
Sweden) isogradient centrifugation from fresh heparinized blood samples 
and stored at -70 °C until analyzed. Peripheral blood mononuclear cells 
(PBMCs) were washed three times with phosphate buffered saline (PBS)
(Lonza, Verviers, Belgium) and re-suspended in serum-free X-VIVO 15 
culture medium (Lonza). CD4+ memory T cells in studies II and IV were 
separated from freshly isolated PBMCs by one-step magnetic depletion of 
naïve CD4+, CD45RA+, CD8+, γ/δ, B, natural killer (NK), dendritic, and 
erythroid cells, monocytes and granulocytes (Miltenyi Biotec, Gladbach, 
Germany). Cells were lysed in Qiagen RLT lysis buffer (Qiagen, Hilden,
Germany) for reverse transcription quantitative polymerase chain reaction
(RT-qPCR) and stored at -70 °C until analyzed. According to flow cytom-
etry analysis, the purity of the CD4+CD45RO+memory cell preparations 
was typically greater than 93%.
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In study III, Th17 cells were sorted after 72 h PBMC stimulation. To ex-
amine Th17 immunity, 2 x 105 PBMCs/well were cultured in 200 μl vol-
ume, in triplicate for 40 h and 72 h, using 96-well round-bottom plates 
(Thermo Scientific, Waltham, MA). Cells were stimulated with plate-
bound anti-CD3 (5 μg/ml in PBS, BD Pharmingen, San Diego, CA) and 
soluble anti-CD28 (1 μg/ml, BD Pharmingen). Stimulated cells were either 
collected and lyzed in Qiagen RLT lysis buffer (40 h; Qiagen, Hilden, Ger-
many) for RT-qPCR or collected and labelled with the IL-17 secretion as-
say kit (72 h; Miltenyi Biotec, Gladbach, Germany) followed by optional 
staining with anti-CD4-allophycocyanin. Th17 cells were isolated using 
FACSAria II (BD Biosciences, San Jose, CA, USA). Sorted CD4+ Th17high 
and CD4+ Th17int cells were lysed in Qiagen RLT lysis buffer (Qiagen, 
Hilden, Germany) for RT-qPCR.
6.2.2 Flow cytometry and cytokine analyses
The purity of CD4+ memory T cells in study II and IV was regularly as-
sessed during the study by staining the population of CD4+CD45RO+ cells 
with the following surface antigens: CD4-PE, CD3-PerCP, CD45RO-APC,
and CD45RA-FITC (BD Biosciences, San Jose, CA, USA). The isotype 
controls used were IgG1-FITC, IgG1-APC, IgG1-PerCP, and IgG1-PE (BD 
Biosciences, San Jose, CA, USA).
To verify our results for IFN-γ expression at the protein level, the analysis 
of IL-17 and IFN-γ secretion in study III was performed with samples from
two autoantibody-negative children, three children with advanced beta-cell 
autoimmunity, and two children with type 1 diabetes. Frozen PBMCs were 
thawed and allowed to recover in X-VIVO 15 culture medium (Lonza,
Verviers, Belgium) at 37 °C for four hours. The cells were subsequently 
stimulated for 72 h as freshly isolated PBMCs. After stimulation, the cells 
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were labelled with IL-17-allophycocyanin and IFN-γ-PE secretion assay 
kits (Miltenyi Biotec, Gladbach, Germany), CD4-FITC, and 7-aminoacti-
nomycin D (7-AAD). Viable CD4+ T cells were analyzed and single- or 
double-positive IL-17 and IFN-γ cells were sorted and further analyzed
with RT-qPCR.
In study IV, we analyzed the levels of 30 cytokines, chemokines, and 
growth factors from the DIABIMMUNE birth cohort samples with a cus-
tomized 38-plex kit complemented with the Human High Sensitivity T Cell 
Panel - Immunology Multiplex Assay (Merck, Darmstadt, Germany). The 
samples from the young children’s cohort were analyzed with the Human 
TH17 Magnetic Bead Panel - Immunology Multiplex Assay (Merck, Darm-
stadt, Germany) complemented with a custom 3-plex assay for EGF, 
sCD40L, and TGF-α. Samples from different countries were analyzed 
mixed on plates. Luminex analyses were performed in single reactions. 
Quantification of the markers was performed with the Bio-plex 200 Lu-
minex instrument and Bio-Plex Manager software (Bio-Rad, Hercules, CA, 
USA). The concentration of each marker was determined from an eight-
point standard curve using five-parameter logistic regression. The mini-
mum detectable concentration (MinDC) was determined for each marker 
separately using the lowest concentration on the standard curves in the lin-
ear phase (MinDC = c(low)+2SD). The samples below MinDC were given 
a value of 50% of MinDC.
6.2.3 Serum and plasma 25-hydroxyvitamin D and 1,25-dihy-
droksyvitamin D measurements
The 25(OH)D concentration was measured from serum and plasma sam-
ples using an enzyme immunoassay (EIA) method (IDS OCTEIA 25-Hy-
droxyvitamin D kit [Immunodiagnostic Systems, Boldon, UK]). The intra-
64
and inter-assay coefficients of variation were 3.6% and 3.7% for study I
and 3.1% and 1.4% for study II. Quality control was ensured by participat-
ing in the vitamin D External Quality Assessment Scheme (DEQAS, Char-
ing Cross Hospital, London, UK). Different Vitamin D concentrations were 
categorized as deficiency <25 nmol/l, insufficiency 25–49 nmol/l, suffi-
ciency 50-75 nmol/l, and optimal >75 nmol/l in study I and <25 nmol/l, 25-
50 nmol/l, 50-80 nmol/l, and >80nmol/l, respectively, in study II.
The 1,25(OH)2D concentration was measured from plasma samples using 
a commercial EIA method (IDS 1,25-Dihydroxy Vitamin D EIA kit [Im-
munodiagnostic Systems, Boldon, UK]). The intra-assay coefficient of var-
iation was 0.02%.
6.2.4 Amphiregulin ELISA
Undiluted plasma samples were analyzed for amphiregulin with the com-
mercial Human Amphiregulin ELISA kit (Sigma-Aldrich, Saint Louis, 
Missouri, USA) according to the manufacturer’s instructions. 
6.2.5 HLA genotyping and analysis of diabetes-associated autoanti-
bodies
The HLA genotyping of major type 1 diabetes-risk DR-DQ haplotypes of 
the study subjects in studies II, III, and IV was performed with a PCR-
based lanthanide-labeled hybridization method using time-resolved fluo-
rometry for detection, as previously described [230].
Specific radiobinding assays were used to quantitate diabetes-associated 
antibodies IAA, GADA, IA-2A and ZnT8A, as described elsewhere [231].
The cut-off levels used were 2.80 relative units (RU) for IAA, 5.36 RU for 
GADA, 0.78 RU for IA-2A, and 0.61 RU for ZnT8A, covering the 99 per-
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centiles in more than 350 non-diabetic Finnish children. Islet cell antibod-
ies were measured using an indirect immunofluorescence method with a
cut-off value of 2.5 Juvenile Diabetes Foundation units. In study II, assays 
were performed three times at each study center visit and at least twice in 
study III to ensure persistent autoantibody formation. In study IV, only 
subjects negative for autoantibodies were included.
6.2.6 Reverse transcription quantitative polymerase chain reaction
(RT-qPCR)
In studies II and IV, the total RNA from CD4+ memory cells and in study 
III the RNA from PBMCs was isolated with the Qiagen RNAeasy Mini Kit 
(Qiagen). The RNA from isolated Th17 cells in study III was extracted 
with the RNeasy Plus Micro kit (Qiagen). The random hexamer priming of 
a high-capacity cDNA reverse transcription kit was used to synthesize 
cDNA (Applied Biosystems, Foster City, CA). The StepOne Plus instru-
ment and TaqMan Fast Master Mix (Applied Biosystems, Foster City, CA) 
were used to perform qPCR. The relative expression was calculated with
the 2-∆∆Ct method described by Livak and Schmittgen [232].
6.2.7 Metabolic parameters
The results regarding C-peptide levels, glucose concentrations in the oral 
glucose tolerance test, and HbA1c levels in study III were received from 
collaborators.
6.2.8 Stool sample collection, DNA isolation and microbiome analy-
sis
Collection of fecal samples and DNA extraction in the birth cohort sam-
ples in study IV were performed as previously described [202, 233, 234].
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16s sequencing and microbiome analysis was performed essentially as de-
scribed in [233].
6.2.9 Statistical analyses
In study I, analyses were performed with PASW Statistics for Windows. 
The data were normally distributed and hence the Student’s t-test was used 
in study I to compare 25(OH)D concentrations. To analyze the proportion
of cases and controls in different vitamin D level groups, Pearson’s χ2 test 
was used. 
The statistical analyses in studies II, III, and IV were performed with 
GraphPad Prism 4.03 to 8.30 software (GraphPad, La Jolla, CA), with the 
exception of correlation analyses, which were performed with SPSS 20 to 
25 software (IBM, Chicago, IL). In study II, normally distributed data were
analyzed with one-way ANOVA and the unpaired Student’s t-test. The 
non-parametric Kruskal-Wallis test, Dunn’s test and Mann-Whitney U-test 
were used for comparisons between groups in the studies. The non-para-
metric Spearman test was used to study correlations. In study III, log10-
transformed data were analyzed with one-way ANOVA and the unpaired 
or paired Student’s t-test. The two-tailed Fisher’s exact test was used to 
analyze dichotomized data. In study IV, longitudinal analysis of the serum 
cytokine levels in different countries was performed with a linear regres-
sion model. The relationships between different taxa of gut bacteria and 
circulating cyto-, chemokines, and growth factors were analyzed with a lin-
ear mixed effects model, correcting for age, country of origin, and random 
effects (process batch and subject ID). P-values < 0.05 were considered 
significant in all studies. The P-values for differences were not corrected 
for multiple testing, except for the analysis of the relationship between the 
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gut microbiome and circulating cytokines in study IV, where the Benjamin-
Hochenberg method was used.
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7 Results and discussion
7.1 No differences in 25(OH)D concentrations during the first tri-
mester of pregnancy in mothers with healthy children compared 
to mothers with children who later developed type 1 diabetes (I)
Maternal vitamin D deficiency and its role in fetal development has been 
assessed in numerous studies. One study determined that a low maternal 
vitamin D intake via food was associated with a higher risk of islet autoim-
munity in the offspring [235]. Another study observed that the maternal 
intake of cod-liver oil reduced the risk of the offspring developing type 1 
diabetes either due to vitamin D or the n-3 fatty acids eicosapentaenoic acid 
or docosahexaenoic acid [236]. In one study, published shortly after ours,
lower serum 25(OH)D concentrations during late pregnancy were in fact 
associated with the risk of the child developing type 1 diabetes [237].
Our study investigated whether the vitamin D status during the first tri-
mester of pregnancy was associated with the risk of type 1 diabetes in the 
offspring. Serum samples from mothers with healthy children and mothers 
with type 1 diabetic children were compared and no differences were ob-
served. The mean 25(OH)D concentration during pregnancy was 43.9 
nmol/l for the case mothers (n = 343; SD 16.9) and 43.7 nmol/l for the 
control mothers (n = 343; SD 16.6; p = 0.70). The samples available from 
pregnancies with a healthy sibling (n = 137) showed no differences com-
pared to samples from pregnancies with a type 1 diabetic child when cal-
culated using a season-standardized mean (44.1 nmol/l vs. 44.7 nmol/l; p =
0.60). No differences were seen in the proportions of case and control 
mothers in different 25(OH)D groups (p = 0.88). There was no difference 
in the 25(OH)D concentration when groups stratified by disease onset were 
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compared (0–3 years, 44.0 nmol/l; n = 177 vs. 4–7 years, 43.9 nmol/l; n =
154, p = 0.96).
The serum 25(OH)D concentration is known to be affected by seasonal dif-
ferences in sunlight exposure. In this study, case and control samples were 
matched to be collected on the same date. Even though 25(OH)D is quite 
stable during storage, there might have been some degradation. This was 
evaluated in our study by measuring samples that had been stored for dif-
ferent times, and no difference was observed in the mean concentrations. 
Another study measured two year-old samples from the Finnish Maternity 
Cohort and also measured low concentrations (35.7 and 54.2 nmol/l in the 
first trimester and 40.5 and 59.3 nmol/l postpartum) with the same method 
in the same laboratory [238]. Despite the difference in maternal 25(OH)D 
concentrations, the concentrations in children at the age of 14 months were
similar (63.0 vs. 66.0 nmol/l). This indicates that the effect of maternal 
25(OH)D concentrations might not be as long-lasting. 
The results of our study indicate that a decreased 25(OH)D concentration 
during the first trimester of pregnancy is not a risk factor for type 1 diabetes 
in the child. A study by Miettinen et al. revealed that two VDR SNPs linked 
with 25(OH)D rather than 25(OH)D concentrations were associated with 
the risk of the child developing type 1 diabetes [239].
However, during later pregnancy, 25(OH)D concentrations might influence 
the risk of developing type 1 diabetes, as observed in a study published 
after ours [237]. The authors reported that mothers of children with type 1 
diabetes had lower 25(OH)D concentrations than mothers with healthy 
children during the last trimester of pregnancy (65.8 nmol/l vs. 73.1 
nmol/l). The storage time of the samples was similar to our study (samples 
taken during 1992–1994), and these samples were also matched for sea-
sonal changes. 
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Moreover, the amount of sunlight exposure is similar in Finnish and Nor-
wegian women due to the similar latitudes (60° N for Oslo and Helsinki).
However, the methods used differed between these studies and the assay 
CV% values were lower in our study (EIA vs. RIA). The recommendations 
for vitamin D intake in the 1990s were similar in Norway and Finland (5 
μg/d) [240, 241]. The main vitamin D source in Norway is fatty fish, forti-
fied margarine and butter, and cod-liver oil supplements, while the main 
sources in Finland are fish and fish products, fortified milk products, and 
vitamin D supplements [242]. It has been shown that 40% of the population 
in Norway regularly uses cod-liver supplements, almost 60% consumes 
fish liver products, and 57% other vitamin D supplements [243]. Cod-liver 
supplements are problematic as vitamin D sources, since they also contain 
n-3-polyunsaturated fatty acids. It might be that cod-liver oil is a much 
more efficient source of overall vitamin D intake, since supplements con-
tain less vitamin D than oil, and this might have led to the higher 25(OH)D 
concentration observed in the Norwegian study of Sorensen et al. 2012
[237]. Another possibility is that the 25(OH)D obtained from supplements 
in Finland acts metabolically differently in modulating the immune system. 
The main caveat in our study is the fact that all the mothers had low 
25(OH)D concentrations and therefore any differences in effects on the off-
spring were difficult to observe. A follow-up sample from the last trimester 
or a cord-blood sample could have provided more information, and possi-
ble differences in concentrations between the mothers could have been de-
tected. One recent study demonstrated that 25(OH)D concentrations vary 
significantly during pregnancy [244]. The total 25(OH)D concentration 
was lowest during the first trimester, even though it was also low during 
the following two trimesters (median around 40 nmol/l in both). Recently, 
71
it was observed that a low 25(OH)D concentration during the first trimester 
was a risk factor for general adverse pregnancy outcomes [245].
To conclude, Finnish mothers have low 25(OH)D concentrations during 
the first trimester of pregnancy, but this is not associated with the risk of 
type 1 diabetes in the offspring. Others have reported that low 25(OH)D 
concentrations during the last trimester are associated with the type 1 dia-
betes risk in the offspring. This might also have been seen in our study if 
follow-up samples had been available. Therefore, we cannot completely 
exclude the possibility that vitamin D deficiency later during pregnancy is 
a risk factor for the child developing type 1 diabetes and might contribute 
to the high incidence of type 1 diabetes in Finnish children.
7.2 Comparison of vitamin D status and active hormone form of 
vitamin D in Finnish and Estonian children with or without signs 
of beta-cell autoimmunity and its impact on CD4+ T memory cells 
(II)
Studies on the intake of vitamin D and the risk of beta-cell autoimmunity 
or type 1 diabetes have suggested a protective role for vitamin D [192, 236,
246]. However, these types of studies do not tell the whole truth regarding 
the role of vitamin D due to sunlight exposure. Therefore, it is important to 
measure the body’s whole vitamin D content with 25(OH)D measurements. 
Data on 25(OH)D concentrations in newly diagnosed type 1 diabetes pa-
tients are inconsistent [247-250]. Vitamin D has been considered as an anti-
inflammatory factor, and has several target genes in immune cells. In T 
helper cells alone, one study identified 102 target genes that were regulated 
by vitamin D [251]. Recently, it was shown in vitro that vitamin D induced 
human Treg differentiation and TGF-β1 secretion and inhibited Th17 dif-
ferentiation and IL-17 secretion [252]. Since T cell aberrancies have been 
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associated with type 1 diabetes, we wanted to study the possible effects of 
circulating vitamin D concentrations on T cell function at the transcrip-
tional level. One study noted that there was no association between either 
the vitamin D intake or 25(OH)D concentration throughout childhood and 
the risk of beta-cell autoimmunity or type 1 diabetes [253]. 
We aimed to investigate whether there are differences in 25(OH)D concen-
trations between Finnish and Estonian children with or without signs of 
beta-cell autoimmunity due to the much lower incidence of type 1 diabetes 
in Estonia compared to Finland. Estonian children had much lower 
25(OH)D concentrations than Finnish children (Figure 2A, mean 48.4 
nmol/l vs. 74.5 nmol/l, p < 0.001), and this was seen throughout the year 
(Figure 2B). 
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Figure 2. (A) Plasma 25(OH)D is significantly higher in Finnish children (***p < 0.001). 
(B) Seasonal variation in 25(OH)D concentrations in both countries. Horizontal lines rep-
resent means (***p < 0.001, **p < 0.01). 
 
There were no differences in 25(OH)D concentrations between children 
with and without signs of beta-cell autoimmunity (70.6 nmol/l vs. 65.7 
nmol/l). When children with multiple autoantibodies were separated as one 
group, the results remained the same (Aab-: 65.7 nmol/l; 1 Aab: 65.0 
73
nmol/l; >1 Aab: 73.2 nmol/l). These results are in line with one previous 
study [253].
Interestingly, the expression of FOXP3 was elevated in Estonian CD4+ T 
memory cell samples (56.2 vs. 42.8, p < 0.01). In order to determine
whether this was due to a higher 25(OH)D concentration in certain individ-
uals, we separately analyzed only samples having sufficient 25(OH)D con-
centrations from both countries (50–80 nmol/l). The expression of FOXP3 
remained higher (p < 0.001) in the Estonian population. In order to deter-
mine whether vitamin D conversion was locally different, we investigated 
the expression of the vitamin D3 convertase gene CYP27B1 in CD4+ T 
memory cells. Here, we did not find any differences between countries or 
study groups. However, it should be noted that the amount of functional 
enzyme or enzyme activity of vitamin D3 convertase was not investigated.
To examine whether the conversion of 25(OH)D into the active hormone 
1,25(OH)2D was a limiting factor in our study, we extracted and measured 
the active hormone from a small subcohort (N = 56). No differences were 
detected between the countries (Estonia: 100.6 pmol/l; Finland: 96.4 
pmol/l), or between different autoimmunity groups (Aab-: 98.7 pmol/l; 1
Aab: 97.4 pmol/l; >1 Aab: 100.2 pmol/l). Even though Estonian children 
had lower 25(OH)D concentrations, they had the same sufficient amount 
of active hormone in the blood compared to Finnish children. On the other 
hand, it is known that 1,25(OH)2D is strictly regulated and hence differ-
ences in its concentration are difficult to observe. 
In conclusion, there were no differences in the vitamin D status or levels of 
the active hormone form between children with or without signs of beta-
cell autoimmunity, suggesting that vitamin D is not a protective factor 
against beta-cell autoimmunity. Estonian children had lower 25(OH)D con-
centrations than Finnish children, but their 1,25(OH)2D concentrations 
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were at the same sufficient level. Finnish children had nearly optimal vita-
min D levels (~75 nmol/l), whereas Estonian children had insufficient lev-
els (below 50 nmol/l). This suggests that the amount of 1,25(OH)2D needed 
for normal health is obtained without vitamin D supplementation. The ex-
cess 25(OH)D in Finland could potentially even have some negative ef-
fects. This also leads to the question of whether vitamin D obtained from 
supplementation really has any impact on metabolic conversion and func-
tion in the body. Estonian children had higher FOXP3 mRNA expression 
in their CD4+ memory cells, which suggests that the self-regulation in their 
CD4+ T cells is intact and possibly affected by some environmental agents 
that have disappeared from the environment in Finland. No correlations 
between vitamin D and cytokines expressed in CD4+ memory cells were 
observed.
7.3 Th17 immunity and the plasticity of Th17 helper cells in the 
development of type 1 diabetes (III)
The role of Th17 cells in the development of type 1 diabetes has previously
been suggested in both animal [127] and human studies [21, 129-131]. One 
study also detected elevated plasma levels of IL-17 in children with auto-
antibodies compared to autoantibody-negative children [254]. The role of 
plasticity in Th17 helper cells has previously been implicated in animal 
studies in which Th17 cells from BDC2.5 mice induced autoimmune dia-
betes in healthy recipients after conversion into Th1 cells [134, 135]. Po-
tential plasticity in human Th17 cells has been reported before in patients 
with type 1 diabetes. Marwaha et al. [129] demonstrated that Th17 cells 
also expressed FOXP3, even though they originally aimed to investigate 
Treg plasticity. Beriou et al. [255] observed IL-9 expression in Th17 cells 
from type 1 diabetes patients.
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The aim of our study was to determine the changes in Th17 immunity dur-
ing the development of type 1 diabetes. We were also interested in meas-
uring the potential plasticity of Th17 cells. We observed that PBMCs from 
children with advanced signs of beta-cell autoimmunity and impaired glu-
cose tolerance (IGT) displayed upregulation of Th17 immunity (Figure 3).  
Figure 3. Children with advanced beta-cell autoimmunity and impaired glucose tolerance 
or type 1 diabetes show an up-regulation of IL-17 immunity (*p < 0.05, **p < 0.001) in 
PBMCs stimulated for 40 h. (A) Relative mRNA expression of IL-17A, (B) relative 
mRNA expression of IL-17F.
Upregulation of IL-9 and IFN-γ was also observed in PBMCs of these in-
dividuals (Figure 4). The upregulation of Th1 responses has been reported 
in type 1 diabetes before, and Th17 cells converting to a Th1 phenotype 
have been implicated to be especially pathogenic [123, 135]. IL-9-secreting 
Th17 cells induced by TGF-β have previously been observed in type 1 di-
abetes [255]. This could suggest that the T helper cell phenotype in the 
children we studied was more plastic and prone to converting into a more 
pathogenic phenotype.
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Figure 4. Children with advanced beta-cell autoimmunity and glucose intolerance have 
higher IFN-γ (A) and IL-9 (B) mRNA expression in their PBMCs (*p < 0.05, **p < 0.01, 
***p < 0.001).
In order to further evaluate the plasticity of Th17 cells, the cells were sorted 
and their gene expression profile was investigated. The gating strategy is 
illustrated in Figure 5.
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Figure 5. Identification of IL-17-secreting T helper cells for FACS analysis and sorting. 
Lymphocytes were first identified in the light scatter and gated further for CD4 and IL-17. 
Purified cells were subjected to RT-qPCR analysis of IL-17A, IL-17F, IFN-γ, and IL-9. 
 
We gated cells with a strict IL-17 high gate to ensure purity of these cells, 
but also investigated the population of intermediate IL-17 producers. To 
investigate the amount of plasticity in these cells, we used the amount of 
IFN-γ mRNA expression divided by the IL-17 mRNA expression as a plas-
ticity index. We observed that children with advanced beta-cell autoim-
munity and IGT had elevated IFN-γ/IL-17 ratios, i.e. plasticity indices, in 
both Th17int cells and Th17high cells (Figure 6). This suggests that they 
potentially harbor Th17 cells converting into a Th1/Th17 phenotype close 
to disease diagnosis. These results are in line with previous findings from 
animal studies [134, 135]. We did not find any evidence that Th17 cells 
originated from thymic-derived Tregs, because the expression of Helios, a 
marker of thymic-derived Tregs, was low in sorted Th17 cells and did not 
differ between the groups. Also, the expression of FOXP3 was similar in 
Th17 cells from all groups. Moreover, Kunicki et al. demonstrated that the 
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percentage of Th17 cells overlapping with Treg cells in their analysis was 
rather low (3.04%) [256].
Figure 6. Children with advanced beta-cell autoimmunity and glucose intolerance show 
higher IFN-γ/IL-17 ratios in the sorted Th17int cells and Th17high cells compared to
healthy children (***p < 0.001). The IFN-γ/IL-17 ratio is also higher in Th17high cells of 
type 1 diabetes children compared to healthy controls (**p < 0.01).
The Th17 plasticity index also correlated with both HbA1c levels and 
plasma glucose concentrations in the oral glucose tolerance test, reflecting
the function of beta cells (Table 5).
Table 5. The ratio of IFN-γ/IL-17 from Th17high cells correlated with the fasting glucose 
concentration, glucose concentration after the oral tolerance test, and HbA1c.
IFN-γ/IL-17
Glucose mmol/l (0 h) r = 0.81, p = 0.05
Glucose mmol/l (2 h) r = 0.94, p < 0.01
HbA1c r = 0.89, p < 0.05
Our results suggest that the Th17/Th1 plasticity in the periphery is a phe-
nomenon of advanced autoimmunity and glucose intolerance in the disease 
development process for type 1 diabetes. It has been shown in mice that 
Th17 cells are present early but remain inactive [257]. The mechanisms 
IF
N
- ??
 / 
IL
-1
7
H C IG T T 1 D
0 .0
0 .1
0 .2
0 .3 * * *
p = 0 .0 9
IF
N
- ?
 / 
IL
-1
7
H C IG T T 1 D
0 .0
0 .1
0 .2
0 .3 * * *
* *
T h 1 7 in t T h 1 7 h ig h
79
behind Th17 activation were not investigated in our work, but the gut mi-
crobiota is considered to be an essential factor in the regulation of mucosal 
and peripheral immunity. It has been noted before that Candida albicans
induces IL-1β from monocytes, which results in IFN-γ and IL-17 secretion 
from Th17 cells, while Staphylococcus aureus induces IL-17 and IL-10 se-
cretion from Th17 cells [139]. This could suggest the involvement of these 
microbes in our study samples, and it would be interesting to examine the 
relationship between alterations in the gut microbiota and the activation of 
Th17 immunity. Liu et al. observed that TGF-β- and IL-6-induced Th1 cells 
convert to Th17 cells through Runx1 in the gut of a mouse model of colitis 
[258].
In mice models, it has been seen that colonization of the gut with SFB re-
sulted in the differentiation of antigen-specific Th17 cells in the small in-
testine [259-261], and that this resulted in enhanced resistance to the bac-
terium Citrobacter rodentium [259]. Wu et al. reported that SFB-induced 
Th17 cells were able to trigger autoimmune arthritis in mice [262]. How-
ever, few studies have addressed these phenomena in humans. A study by
Atarashi et al. revealed that bacterial strains needed to adhere to epithelial 
cells in order to induce Th17 cells [263]. From one fecal sample from a 
patient in the US, they isolated 20 strains, most of them belonging to Clos-
tridium, Bifidobacterium, and Ruminococcus species, that were able to in-
duce Th17 cells in mice. In a study by Tan et al., the human symbiont 
Bifidobacterium adolescentis was able to induce Th17 cells in the gut of 
mice and to exacerbate autoimmune arthritis [264]. The authors further ob-
served that IBD patients had more Bifidobacterium-related species with a 
high abundance in their gut compared to healthy control data from the Me-
taHIT database. They also tested six different off-the-shelf probiotic prod-
ucts and found that four of them were able to induce intestinal Th17 cells 
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in mice [264]. Vatanen et al. [234] compared the microbiome of children 
from Finland, Estonia, and Russia. They found that even though Finnish 
and Estonian children were breastfed longer than Russian children, the ge-
nus responsible for metabolizing human milk oligosaccharides (HMOs) 
was in fact Bacteroides in Finland and Bifidobacterium in Russia [234].
They noticed that one possible mechanism contributing to an increased risk 
of autoimmunity in Finland and Estonia could be that the LPS derived from 
Bacteroides did not induce endotoxin tolerance compared with E. coli-de-
rived LPS [234]. We have also observed that Bifidobacterium longum neg-
atively correlates with Th17 immunity in healthy controls (unpublished re-
sults). This is an interesting aspect to be investigated further and it could 
raise a question of whether off-the-shelf probiotic products should be rec-
ommended for individuals at risk of autoimmune diseases.
In MS patients, it has been reported that vitamin D supplementation in-
creases serum TGF-β [251]. If TGF-β induces Th1 cells to convert to Th17 
cells [258] and TGF-β inhibits IL-22 in Th17 cells [41], this might lead to 
more pathogenic cells in Finland, where vitamin D supplementation is 
commonly implemented. Previously, it has also been observed that Finnish 
mothers have elevated TGF-β levels in their breast milk compared to moth-
ers from other European countries [265], and hence this priming of T cells
might already start during breastfeeding.
The Th17 memory cell population and IL-17A concentration in serum have 
been reported to be much higher in MS patients and neuromyelitis optica 
(NMO) patients compared to healthy controls [266]. Annunziato et al. also 
demonstrated the presence of Th17 and Th1/Th17 cells in the gut of pa-
tients with Crohn’s disease [267].
Results regarding Th17/Th1 plasticity in other autoimmune diseases are 
similar to our findings. Comparable Th1/Th17 plasticity has been observed
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in CD4+CD45RA+ cells of patients with autoimmune polyendocrinopa-
thy-candidasis-ectodermal dystrophy (APECED) compared to controls 
[268]. Already in 2010, Nistala et al. demonstrated that Th17 cells in the 
inflamed joints of children with inflammatory arthritis expressed a Th1
phenotype and converted into Th17/Th1 (RORC- and T-bet-expressing)
cells under low TGF-β and high IL-12 concentrations [136]. Kotake et al. 
reported that Th17 cells present in the peripheral blood of early RA patients 
were derived from Th1 cells (CD161+ Th17 cells) [269]. They stated that 
anti-IL17 antibodies could potentially be therapeutically effective in pa-
tients with early RA. Basdeo et al. detected ex-Th17 cells that converted to 
Th1 cells in the inflamed joints of RA patients and observed that these cells 
secreted more proinflammatory cytokines upon stimulation and were re-
sistant to suppression of Tregs [270]. This might also be true in the preclin-
ical phase of type 1 diabetes. It is possible that these highly inflammatory 
Th17 cells are the first ones in close proximity to the pancreas and appear 
in the circulation close to the diagnosis. Since we could not see any upreg-
ulation of FOXP3 in the Th17/Th1 cells in children with impaired glucose 
tolerance, it might support the idea that these cells are resistant to self-reg-
ulation.
To conclude, children with advanced beta-cell autoimmunity express signs 
of Th17 immunity, as has been observed in type 1 diabetes patients before. 
Stimulated PBMCs from children with advanced beta-cell autoimmunity 
express higher IL-17F, IFN-γ, and IL-9 mRNA levels, and higher IFN-γ 
expression was observed in sorted Th17int and Th17high cells from these 
children. Importantly, the IFN-γ/IL-17A mRNA ratio in Th17high cells 
correlated with metabolic parameters, suggesting that Th17 immunity close 
to disease diagnosis and the plasticity of these cells potentially accelerates 
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disease development due to the gain of the Th1 phenotype fueling cytotox-
icity. This is a novel finding and these markers may be used in the identifi-
cation of disease progressors among children with beta-cell autoimmunity. 
The use of ROR inhibitors as therapeutic agents has been shown to be ef-
fective in a NOD mouse model [141]. In that study, a RORα/γ inverse ag-
onist, SR1001, was used and this reduced diabetes incidence and insulitis 
in the treated mice. SR1001 reduced proinflammatory cytokine expression, 
especially that of Th17-related cytokines, reduced autoantibody produc-
tion, and increased the frequency of Tregs [141]. Xiao et al. identified three 
inverse agonists for RORγt (TMP778, TMP920, and GSK805) that were 
able to suppress Th17 responses and disease in EAE mice [271]. In psoria-
sis and psoriatic arthritis, there are already FDA-approved antibodies tar-
geting Th17 immunity [272-275]. We did not test the antigen specificity of 
the Th17 cells. This would have been very interesting and is something to 
consider in future studies. On the other hand, in vitro experiments have 
demonstrated that IL-17A together with IL-1β and IFN-γ increase the fre-
quency of apoptotic beta cells and increase the beta-cell stress response, 
suggesting that beta-cell death may be a bystander effect without antigen 
specificity.
In conclusion, the up-regulation of Th17 immunity and the plasticity of 
Th17 cells is not associated with the early stages of type 1 diabetes disease 
development, but rather with advanced disease pathogenesis. These can po-
tentially be used as a biomarker for disease progression and as a tool for 
identifying high-risk individuals for inclusion in secondary intervention tri-
als and for immune monitoring in these trials. The upregulation and plas-
ticity of Th17 immunity may be a result of alterations in the microbiota on
mucosal surfaces, such as the gut, where Candida and some bacteria could 
be the potential drivers.
83
7.4 Mucosal immunity in young Russian, Estonian, and Finnish 
children – focus on epidermal growth factor and interleukin-22 
(IV)
Environmental factors modulate the development of the immune system 
and influence the risk of autoimmune and other immune-mediated diseases,
as seen in differences in the incidence of allergies, asthma, and autoimmune 
diseases between Finnish, Estonian, and Russian Karelian populations 
[276-279].
To elucidate some of the molecular drivers for this difference, we investi-
gated the development of the immune system in infants participating in the 
DIABIMMUNE study during the first three years of life in Russian Karelia, 
Estonia, and Finland by measuring the levels of 30 cytokines, chemokines,
and growth factors in serum samples. Additionally, we validated the results 
from the first phase by analyzing these further in an independent set of 
samples from four-year-old children from Estonia and Finland.
We observed a clear increase in blood levels of circulating cytokines asso-
ciated with Th1 (IFN-γ), Th2 (IL-5 and IL-13), Th17 (IL-17A), and regu-
latory T cell (IL-10) subsets in all countries during the first three years of 
life. For all the Th cytokines listed above and for the cytokines supporting 
the development of different Th subsets, age was a significant driver,
whereas we did not observe differences between the countries in the longi-
tudinal analysis. The maturation profile was similar between the countries.
Analysis of the birth cohort samples for growth factor, cyto-, and chemo-
kine levels revealed that Russian children had significantly increased cir-
culating levels of EGF, sCD40L, and CXCL11 (ITAC) compared to chil-
dren from Estonia and Finland during the study period. As we noticed dif-
ferences in the levels of EGF and TGF-α between the countries in the birth 
cohort, we decided to include AREG in our analyses to examine whether 
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there is any specificity in the EGFR ligand-level differences. When we ex-
amined concentrations of EGF, TGF-α, AREG, and sCD40L in four-year-
old children in Estonia and Finland, we observed that Estonian children had 
elevated levels of EGF and sCD40L compared to Finnish children 
(p < 0.001). In turn, Finnish children had higher concentrations of TGF-α 
than Estonian children (p < 0.001). No difference was observed in AREG 
concentrations.
Both EGF and TGF-α are high-affinity ligands for EGFR, causing prolif-
eration and differentiation of their target cells [280]. Despite similar affin-
ities, they possess a different potency to activate EGFR-mediated signaling,
with TGF-α being more potent [281, 282]. Upregulation of TGF-α in Finn-
ish children could be an adaptive mechanism to compensate for the lower 
EGF levels. However, since EGF and TGF-α activate slightly different sig-
naling cascades and modify the turnover of internalized EGFR-ligand com-
plexes differently [281], the altered levels in Finnish children most likely 
modify the function of the cells expressing EGFR, including intestinal ep-
ithelial cells.
We next analyzed the relationship between EGF and sCD40L, and ob-
served that in Estonia and Finland, these factors showed a strong correla-
tion throughout the study period (Table 6). In Russia, a similar correlation 
was only detected in six-month-old children. In children from the young 
children’s cohort, we observed a strong correlation in both Estonia and Fin-
land (r = 0.69, p < 0.001 and r = 0.58, p < 0.0001).
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Table 6. The correlation of EGF and sCD40L levels at different ages in Russia, Estonia 
and Finland during the three-year study period.
3 months 6 months
12
months 
18
months
24 months 36 months
Russia NS
r = 0.69, 
p < 0.0001
NS NS NS NS
Estonia
r = 0.72, 
p < 0.0001
r = 0.4, 
p < 0.05
r = 0.65, 
p < 0.01
r = 0.65, 
p < 0.01
r = 0.84, 
p < 0.0001
r = 0.5, 
p < 0.05
Finland
r = 0.8, 
p < 0.001
r = 0.5, 
p < 0.001
r = 0.48, 
p < 0.01
r = 0.5, 
p < 0.05
NS
r = 0.74, 
p < 0.0001
When we further analyzed samples from the young children’s cohort, we 
observed that the concentrations of circulating IL-17A and IL-6 were 
higher in Finnish than in Estonian samples (p < 0.01). The concentrations 
of IFN-γ and IL-12p70 were also higher in Finnish samples compared to
Estonian samples (p < 0.01). However, the protein concentrations of IL-22
and IL-1β were at the same level in both countries. These results suggest 
that environmental factors in Finland have changed towards a Th1/Th17
direction, potentially promoting the development of immune pathologies. 
As EGF was consistently higher in Russian and Estonian children, we 
aimed to characterize the relationship between effector pathways and EGF 
in more detail. When we divided the children from the young children’s
cohort into EGFlo and EGFhi groups based on the overall median value,
we observed that Finnish children expressing high levels of EGF had higher 
levels of CCL20 and IL-13 compared to Estonian low and high EGF ex-
pressors and Finnish low EGF expressors (p < 0.05 to p < 0.01). Estonian 
EGF low expressors had lower IFN-γ mRNA expression in CD4+ memory 
cells than Estonian high EGF expressors and Finnish children with low or 
high expression of EGF (p < 0.05 to p < 0.01). Previously, it has been noted
that the EGF receptor is under regulation by IFN-γ [283]. It appears that in 
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Estonia there is a link between IFN-γ and EGF, but this link has been lost
in Finland. In the Finnish EGFlo expressors, we detected a modest correla-
tion between TGF-α and IFN-γ mRNA expression in CD4+ memory cells,
further supporting the replacement of EGF by TGF-α in Finland (r = 0.371, 
p < 0.05). Furthermore, there appears to be a connection between the levels 
of circulating EGF and CCL20 and IL-13 in Finland, suggesting that EGF 
may modulate T cell functions more broadly. Kim et al. observed that 
CCL20 indirectly activated the EGF receptor, and this led to the exagger-
ated production of MUC5AC mucin from human airway epithelial (NCI-
H292) cells [284]. Interestingly, TGF-α also induced activation of ERK 
1,2-dependent production and secretion of CCL20 from airway epithelial 
cells. We observed higher TGF-α levels but lower EGF levels in Finnish 
children. Finnish children with high EGF had higher CCL20 levels com-
pared to Finnish children with low EGF or Estonian children in general, 
suggesting that in Finland, a functional switch between EGF and TGF-α 
has occurred. Therefore, the consequence of altered levels of EGF and 
TGF-α in Finnish children could be functional alterations of mucosal im-
munity. CCL20, the only known ligand for CCR6, is expressed at high lev-
els on Th17 cells, regulating the recruitment and migration of these cells in 
the gut-associated lymphoid structures [285]. Chen et al. reported that IL-
22 was able to inhibit the secretion of CCL20 in Helicobacter pylori-in-
fected epithelial cells in vitro, and an inverse association was also seen in 
tissue samples from patients with H. pylori infection [286]. Increased se-
cretion of mucins and CCL20 could alter the capture of antigens and mi-
gratory patterns of mucosal immunity-associated Th17 cells in the gut mu-
cosa.
IL-13 has also been linked with EGFR. Zhen et al. observed that CCL20 
and IL-13 both influenced the production of mucus in airway epithelial 
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cells with distinct pathways [287]. Despite sporadic observations of EGFR 
expression on hematopoietic cell lines, the expression and functional sig-
nificance of EGFR in immune cells has only recently been recognized. In 
a study by Minutti et al., T cell receptor-induced expression of EGFR and 
ligation of AREG was essential for IL-33-induced secretion of IL-13 from 
activated Th2 cells in mice [288]. A recent study reported that activated 
human T cells express EGFR and that the inhibition of EGFR signaling 
decreased cell proliferation and the production of Th1/Th2/Th17 cytokines 
[289]. In a study by Zaiss et al., AREG, a mast cell-derived ligand with low 
affinity for EGFR, significantly enhanced Treg functions in vivo and in 
vitro [290]. These data suggest that EGFR signaling may be an important 
direct regulator of T cell functions in humans and requires more investiga-
tion in the future. 
When we analyzed the mRNA expression of T helper memory cells in sam-
ples from the young children’s cohort, we observed that the only marker 
that differed between countries was IL-22, as it was significantly higher in 
Estonian children than Finnish children (p < 0.001). There was no differ-
ence in IL-17A, IFN-γ, or FOXP3 mRNA expression between the coun-
tries.
IL-22 is a crucial regulator of intestinal immunity, inflammation, and tissue 
repair. The IL-22 receptor is widely expressed in non-immune cells, but is 
absent from immune cells, and IL-22 mainly influences epithelial cells, 
hepatocytes, pancreatic acinar cells, and related stem cells [291]. IL-22 in-
duces the secretion of anti-microbial peptides, such as β-defensin-2 from 
gut epithelial cells. IL-22 is important in protective immunity against 
Citrobacter rodentium in mice. Zheng et al. demonstrated that IL-22 
knockout mice died from Citrobacter rodentium infection, and histological 
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samples from these mice displayed increased mucosal hyperplasia and sub-
mucosal inflammation compared to wild-type mice [214]. One study re-
ported results from in vitro experiments in which the stimulation of 
keratinocytes with the supernatant of Th22 cells or recombinant IL-22 and 
TNF-α successfully inhibited Candida albicans infections and preserved 
epithelial health [215]. Since it has been proposed that the role of IL-22 is 
protective in acute inflammation and detrimental in chronic inflammation,
the results suggest that chronic inflammation in Finland could support the 
protective role of IL-22 in Estonia and a more inflammatory role in Finland
[292]. Previously, it has been observed that CD4+ memory cells that pro-
duce IL-22 can be Candida albicans-specific [293]. Possible yeast infec-
tions and urinary tract infections by E. coli could explain the IL-22 expres-
sion in memory cells in Estonian children. So far, this has not been inves-
tigated. One approach to further study this aspect would be to analyze the 
mycobiota composition of these children. One recent study observed that 
the onset of autoimmunity in a NOD mouse model was associated with 
modifications to the structure of the mucus layer and the loss of gut barrier 
integrity [294]. These mice carried a transgenic TCR specific for a beta-
cell autoantigen, and it was observed that the loss of integrity led to the 
activation of islet-reactive T cells within the gut mucosa and subsequently 
to the onset of diabetes [294]. If the integrity of the intestinal epithelium is 
damaged to some extent in Finland, this could explain the up-regulation of 
cytokines essential for mounting cytotoxic responses against intracellular 
pathogens.
In this study, we only observed a few longitudinal differences between the 
countries, EGF showing the most striking differences. While the gut mi-
crobiota is considered an important regulator of peripheral immunity, we 
did not observe any significant correlations between different gut bacterial 
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taxa and the levels of circulating cytokines, chemokines, or growth factors. 
Very recently, Ruohtula et al. reported that the gut microbiota greatly in-
fluences the maturation of circulating regulatory T cells in early life when 
Estonian and Finnish children were compared [295]. In a study by Schirmer 
et al., the authors found that gut microbial signatures correlated with im-
mune responses from stimulated PBMCs [296]. Here, we analyzed the lev-
els of circulating soluble factors, thus presenting sliding average values at 
a given time and making it difficult to establish a link between the gut mi-
crobiota and circulating cytokines. On the other hand, there might be other 
factors affecting the regulation of EGF levels in the systemic circulation.  
One example of such a factor has been reported in a recent study in which
vitamin D supplementation was demonstrated to decrease EGF expression 
in type 1 diabetes patients [297]. It was further shown that 1,25(OH)₂D 
alters membrane trafficking and downregulates growth signaling of the 
EGF receptor [298].
In conclusion, our results suggest that lower concentrations of EGF in Fin-
land could contribute to enhanced Th1 and Th17 immunity. We further 
suggest that decreased expression of EGF and sCD40L in Finnish children 
may contribute to the disruption of epithelial integrity and intestinal home-
ostasis, potentially mediated by the decreased and modulated activity of 
antigen-experienced memory T helper cells. This, in turn, may contribute 
to the development of systemic low-grade gut inflammation, resulting in 
elevated levels of inflammatory cytokines in the periphery and favoring the 
development of immune-mediated diseases. Environmental factors that re-
duce EGF levels in early infancy in Finland are yet to be revealed.
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8 Conclusions
Study I. A low concentration of vitamin D during the first trimester of 
pregnancy is not associated with type 1 diabetes in the offspring. Overall,
Finnish mothers have insufficient 25(OH)D concentrations during the first 
trimester of pregnancy. Results from other studies have shown that low vit-
amin D concentrations during the last trimester are associated with type 1 
diabetes in the offspring, but the results of these studies must be interpreted 
with caution due to simultaneous consumption of fatty acids. Follow-up 
samples from a later stage of pregnancy or at the time of birth would also 
have provided more information in our study. It is possible that vitamin D 
deficiency later during pregnancy is a risk factor for the child developing
type 1 diabetes. This could be one environmental factor contributing to the 
high incidence of type 1 diabetes in Finnish children. However, our current 
results do not indicate that a decreased vitamin D status during early preg-
nancy is a risk factor for the offspring developing type 1 diabetes later in 
life.
Study II. We did not observe differences in the vitamin D status or levels
of the active hormone form between children with or without signs of beta-
cell autoimmunity. Moreover, no differences were observed in the vitamin 
D convertase CYP27B1 expression in CD4+ T helper memory cells be-
tween different autoimmunity groups or between countries. Interestingly,
Estonian children had lower 25(OH)D concentrations than Finnish chil-
dren, but their 1,25(OH)₂D concentrations were at the same sufficient level. 
This may suggest that the amount of 1,25(OH)₂D needed is obtained with-
91
out additional vitamin D supplementation. Estonian children had higher ex-
pression of FOXP3 in their CD4+ memory cells, suggesting that factors 
other than vitamin D sustain the activity of regulatory mechanisms in T 
cells. In the light of the current study, vitamin D is not a protective factor 
against beta-cell autoimmunity or type 1 diabetes.
Study III. Upregulation of Th17 immunity and increased expression of 
IFN-γ in Th17 cells is associated with advanced beta-cell autoimmunity 
and disturbances in glucose metabolism. Th17 immune markers may have 
potential as novel biomarkers for predicting disease progression. Im-
portantly, Th17 cells may also represent an attractive therapeutic target for 
the pharmacological inhibition of type 1 diabetes-associated immuno-
pathology. Our results suggest that close to a type 1 diabetes diagnosis,
Th17 immunity is increased, and the plasticity of these Th17 cells is a factor
possibly leading to disease development due to their conversion to the Th1
phenotype.
Study IV. We demonstrated lower serum levels of EGF and sCD40L, and
decreased IL-22 mRNA expression in CD4+ T memory cells in Finnish 
children, which may be associated with a disruption of gut epithelial integ-
rity and decreased activity of antigen-experienced memory T helper cells
in these children. This, in turn, may result in low-grade gut inflammation,
generating elevated levels of inflammatory cytokines in the periphery and 
favoring the development of immune-mediated diseases in Finnish children 
compared to Estonian and Russian children.
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8.1 Potential caveats of the studies
Study I. It would have been interesting to compare serum samples from 
different time points of pregnancy to gain more information on vitamin D 
concentrations throughout pregnancy.
Study II. The number of studied individuals was rather small. We could 
have included more samples from additional individuals to ensure that the 
study had sufficient power to detect subtle differences. We did not charac-
terize the phenotype or function of specific T helper subsets, but rather an-
alyzed the whole memory T cell population. Analyses of enzymatic activity 
and enzyme levels of vitamin D convertase would have given more infor-
mation regarding vitamin D conversion.
Study III. Antigen specificity could have been tested on some of the sorted 
Th17 cells to gain more information regarding their role. We only studied 
a limited number of individuals, and a larger prospective longitudinal fol-
low-up study is therefore warranted in the future.
Study IV. The characterization of the EGF receptor in T helper cells and 
the effect of EGF stimulation on T cell phenotypes and responses would 
have been an interesting aspect to study further. The potential of serum 
samples to induce EGFR signaling needs to be evaluated in future studies.
Also, results regarding the mycobiota would have been interesting. Stimu-
lation of PBMCs or human insulinoma cell lines with EGF and IL-22 could 
be an experiment to consider in the future. 
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